



學院舉辦第八屆國際標準化組織中醫藥技術委員會全體大會  
SCM hosts the eighth plenary meeting of International Organisation for Standardisation/Technical Committee 249 on  
Traditional Chinese Medicine



學院委任五位傑出學者及中醫藥界翹楚為榮譽教授  
SCM appoints five eminent scholars and Chinese medicine experts as Honorary Professors



## 目錄 C O N T E N T S

### 專題

Features

學院舉辦第八屆國際標準化組織中醫藥技術委員會全體大會 / 3-4

SCM hosts the eighth plenary meeting of International Organisation  
for Standardisation/Technical Committee 249 on Traditional Chinese Medicine

學院委任五位傑出學者及中醫藥界翹楚為榮譽教授 / 5-6

SCM appoints five eminent scholars and Chinese medicine experts as Honorary Professors

### 研究焦點

Research Focus

卞兆祥教授帶領團隊制定中藥複方臨床試驗報告指引冀提升中藥研究水平 / 7-8

Professor Bian Zhaoxiang leads development of guidelines  
for better reporting of trials of Chinese herbal medicine formulas

呂愛平教授與張戈教授研究團隊研發在體靶向骨肉瘤的基因編輯遞送系統 / 9-10

Professor Lyu Aiping and Professor Zhang Ge's research team develops a targeted delivery system  
for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma

學院成功研發特異性識別和治療腫瘤的適配子 — 天然產物偶合物 / 11

SCM scholars develop tumor-specific aptamer-drug conjugate

學院新開發的「LogicTRN」有助快速尋找複雜疾病的關鍵調控路徑及治療靶基因 / 12-13

“LogicTRN” newly developed by SCM useful for unravelling key pathways and new therapeutic  
targets of complicated diseases

### 臨床觀察

Clinical Observations

臨床研究顯示針灸有助控制體重 / 14-15

Clinical trial proves acupuncture effective for weight control

兩項臨床觀察顯示中醫藥治療慢性腎衰有效 / 16-17

Two clinical studies find Chinese medicine effective for treating chronic renal failure

研究顯示天灸治療有效改善鼻敏感患者生活質量 / 18

Study finds *tianjiu* therapy improves allergic rhinitis patients' quality of life

頭皮針能有效治療兒童自閉症 / 19-20

Scalp acupuncture effective for treating autistic children

### 學術及專業活動 / 21-25

Academic and Professional Activities

### 學院動態 / 26-31

Highlights

### 學生 · 校友 / 32-34

Students · Alumni

### 新面孔 / 35

New Faces

### 聯絡資料 / 36

Contact Us



# 中醫藥學院舉辦 第八屆國際標準化組織 中醫藥技術委員會全體大會

SCM hosts the eighth plenary meeting of  
International Organisation for Standardisation/  
Technical Committee 249 on Traditional Chinese Medicine



逾 200 位中醫藥專家學者聚首浸大參加國際標準化組織中醫藥技術委員會 (ISO/TC 249) 第八屆全體大會

Over 200 experts and scholars gathered on campus to attend the eighth plenary meeting of the International Organisation for Standardisation/Technical Committee 249 on Traditional Chinese Medicine (ISO/TC 249).

香港浸會大學中醫藥學院於 6 月 5 日至 8 日舉辦第八屆國際標準化組織中醫藥技術委員會 (ISO/TC 249) 全體大會，來自 14 個國家和地區的逾 200 名代表、世界中醫藥學會聯合會 18 名代表，以及現任及前任相關省局級官員雲集浸大校園參加會議。今次亦是香港首次作此國際組織全體大會的東道主。

會議期間，除了兩場全體大會外，ISO/TC 249 的六個工作小組也舉行了會議。ISO/TC 249 於全體大會上聽取關於策略工作計劃的報告，以及其六個工作小組的工作進度報告、工作計劃和新建議。

全體大會開幕儀式的主人包括 ISO/TC 249 主席 David Graham 博士、浸大副校長（教與學）周偉立博士、香港特區政府創新科技署生物科技總監彭慧冰博士及國家中醫藥管理局國際合作司朱海東副司長。

The School of Chinese Medicine (SCM) of Hong Kong Baptist University (HKBU) hosted the eighth plenary meeting of the International Organization for Standardization/Technical Committee 249 on Traditional Chinese Medicine (ISO/TC 249) from 5 to 8 June 2017. This was the first time for Hong Kong to host the plenary meeting of this international organisation on traditional Chinese medicine, which was attended by more than 200 delegates from 14 countries and regions, 18 representatives of the World Federation of Chinese Medicine Societies as well as current and former ministerial and provincial officials from the mainland.

In addition to two plenary meetings, meetings of ISO/TC 249's six Working Groups were held on the two days. ISO/TC 249 received at the plenary meetings a report on its Strategic Business Plan and reports on the progress of work as well as plans and new proposals of its six Working Groups.

The opening ceremony of the opening plenary meeting was officiated by Dr. David Graham, Chairman of ISO/TC 249; Dr. Albert Chau, Vice-President (Teaching and Learning), HKBU; Dr. Cecilia Pang, Biotechnology Director, Innovation and Technology Commission, HKSAR Government; and Mr. Zhu Haidong, Deputy Director-General, Department of International Cooperation, State Administration of Traditional Chinese Medicine (SATCM) of PRC.



周副校長在致歡迎辭時說：「香港很榮幸能夠舉辦第八屆 ISO/TC 249 全體會議；香港中西文化薈萃，是中國對外交合作的一個主要視窗，浸大在香港中醫藥界別擔當重要角色，特別是在中醫藥教育、科研、醫療服務、標準化及走向世界等方面貢獻良多，能夠舉辦這個重要的國際會議，匯聚來自世界各地的專家共同制訂中醫藥的國際標準，為中醫藥標準化和走向世界作出獨特貢獻，促進中醫藥發展及人類健康，感到非常鼓舞。」

中醫藥學院院長呂愛平教授率領成員逾百的中國代表團出席第八屆 ISO/TC 249 全體大會。自 ISO/TC 249 於 2009 年成立以來，他一直承擔此重任。

學院於 2014 年獲國家中醫藥管理局確定為 ISO/TC 249 及國際標準化組織健康資訊技術委員會（ISO/TC 215）聯合工作組中方依託單位，負責中醫藥資訊相關國際標準的研究及協調工作。

ISO/TC 249 的工作範疇包括對源於中醫藥的醫療系統制訂標準，涵蓋傳統和現代化中醫藥的醫療系統，目前主要專注於原材料、製成品、醫療儀器及醫療信息的質量和安全性。/

In his welcome address, Dr. Chau said, "Hong Kong, a place where East meets West and an important window for China's international collaboration and exchange, is privileged to host the eighth plenary meeting of ISO/TC 249. HKBU, a key player in the field of Chinese medicine in Hong Kong, in particular in education, research, healthcare services and the standardisation and internationalisation of Chinese medicine, feels honoured and encouraged to host the meeting and assemble experts from different parts of the world on campus to formulate Chinese medicine standards, thereby making unique contribution to the standardisation and internationalisation of Chinese medicine as well as the advancement of Chinese medicine for the benefit of mankind."

Professor Lyu Aiping, Dean of SCM, was head of the China delegation comprising over 100 delegates attending the eighth plenary meeting. He has since the establishment of ISO/TC 249 in 2009 been serving in that important position.

In 2014 SATCM designated SCM as a support unit for the joint working group of ISO/TC 249 and International Organization for Standardization/ Technical Committee 215 on Health Informatics since 2014. In that capacity, the School is responsible for conducting studies on international standards of Chinese medicine informatics and performing related coordination work.

The scope of ISO/TC 249 includes standardization in the field of medical systems derived from ancient Chinese medicine, covering both traditional and modern aspects of these systems. The Technical Committee now focuses on the quality and safety of raw materials, manufactured products, medical devices and informatics. /



周偉立副校長歡迎與會者出席首次由香港作東道主的 ISO/TC 249 全體大會

Dr. Albert Chau welcomed participants of the first-ever plenary meeting of ISO/TC 249 hosted by Hong Kong.



ISO/TC 249 主席 David Graham 博士致開幕辭

ISO/TC 249 Chairman Dr. David Graham delivered the opening address.





路志正教授  
Professor Lu Zhizheng



程京教授  
Professor Cheng Jing



曹洪欣教授  
Professor Cao Hongxin



黃璐琦教授  
Professor Huang Luqi



劉平教授  
Professor Liu Ping

## 學院委任五位傑出學者及中醫藥界翹楚為榮譽教授

SCM appoints five eminent scholars and Chinese medicine experts as Honorary Professors

中醫藥學院於 10 月 21 日舉行第七屆榮譽教授頒授典禮暨研討會。第七屆榮譽教授共有五位，其中曹洪欣教授及劉平教授蒞校接受由校長錢大康教授頒授的委任證書，並於頒授典禮後講演，聽眾包括約 250 位中醫藥學院師生、校友及本地中醫師。一同主持頒授典禮的有副校長（研究及拓展）黃偉國教授、副校長（教與學）周偉立博士及中醫藥學院院長呂愛平教授。

學院自 2004 年開始頒授榮譽教授銜，表彰在中醫藥領域有卓越成就的人士。學院於 2017-18 學年委任了五位著名中醫藥學者為第七屆榮譽教授，包括國醫大師、中國中醫科學院廣安門醫院主任醫師路志正教授，中國工程院院士、清華大學醫學院生物醫學工程系及醫學系統生物學研究中心教授程京教授，中國中醫科學院首席研究員曹洪欣教授，中國

The School of Chinese Medicine (SCM) organised the 7<sup>th</sup> Honorary Professorship Conferment Ceremony-cum-Seminar on 21 October. Two of the 7<sup>th</sup> cohort of SCM honorary professors, namely Professor Cao Hongxin and Professor Liu Ping, attended the Ceremony and received the appointment certificates from Professor Roland T. Chin, President and Vice-Chancellor. Immediately following the Ceremony, the two honorary professors delivered lectures to enlighten the audience of over 250 teachers, students and alumni of SCM as well as local Chinese medicine practitioners. Also officiating at the Ceremony were Professor Rick W.K. Wong, Vice-President (Research and Development); Dr. Albert W.L. Chau, Vice-President (Teaching and Learning); and Professor Lyu Aiping, Dean of Chinese Medicine.

SCM has since 2004 been conferring honorary professorships to recognise persons with distinguished achievements in the Chinese medicine arena. In 2017-18, SCM has appointed the 7<sup>th</sup> cohort of five honorary professors; they are: Professor Lu Zhizheng, National TCM Master, Chief Physician of Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Professor Cheng Jing, Academician of Chinese Academy of Engineering, and Professor of Tsinghua



工程院院士、中國中醫科學院常務副院長黃璐琦教授，以及上海中醫藥大學教授、上海市教育委員會上海高校中醫內科學 E- 研究院首席研究員劉平教授。

呂愛平教授在典禮上致辭時表示，新一屆的榮譽教授長期把才華和努力傾注在中醫藥領域，為中醫藥發展和人類健康做了巨大的貢獻。他期望榮譽教授對學院多加指導，也希望日後能與他們開展交流合作。

研討會上，曹洪欣教授及劉平教授分別以「中醫對突發傳染性疾病的作用」及「臨床病證病機相應不同功效方劑干預肝硬化的效應機制」為題演講。

University's Medical Systems Biology Research Center and Department of Biomedical Engineering, School of Medicine; Professor Cao Hongxin, Chief Researcher of China Academy of Chinese Medical Sciences; Professor Huang Luqi, Academician of Chinese Academy of Engineering, and Executive Vice President of China Academy of Chinese Medical Sciences; and Professor Liu Ping, Professor of Shanghai University of Traditional Chinese Medicine, and Chief Researcher of E-Institute of Chinese Internal Medicine, Shanghai Municipal Education Commission.

Speaking at the ceremony, Professor Lyu Aiping commended the 7<sup>th</sup> cohort of Honorary Professors for their lifelong dedication to the field of Chinese medicine and their outstanding contribution to the development of Chinese medicine and public health. He expressed the wish to benefit from their wise counsel and looked forward to embarking on exchanges and collaborations with them in the future.

At the seminar, Professor Cao Hongxin and Professor Liu Ping delivered talks entitled "Effects of Chinese medicine on infectious diseases" and "Effect mechanism of different efficacy prescription on liver cirrhosis based on clinical disease pathogenesis correspondence" respectively.



曹洪欣教授（前排左三）和劉平教授（前排左四）獲授學院榮譽教授銜

SCM conferred Honorary Professorship on Professor Cao Hongxin (front row, third from left) and Professor Liu Ping (front row, fourth from left).



# 卞兆祥教授帶領團隊制定中藥複方臨床試驗報告指引冀提升中藥研究水平

Professor Bian Zhaoxiang leads development of guidelines for better reporting of trials of Chinese herbal medicine formulas



卞兆祥教授表示，中醫藥臨床研究越來越受到國際生物醫藥界的關注。

Professor Bian Zhaoxiang says that Chinese medicine clinical research is gaining increasing attention in the international biomedical science community.

經過 10 年的努力，由協理副校長兼中醫藥學院臨床部主任卞兆祥教授率領的國際工作小組最近完成中藥複方臨床隨機對照試驗報告規範 (CONSORT — 中藥複方 2017)。

有關論文於今年 6 月在國際知名期刊《內科醫學年鑑》以中英文在網上同步發表，這是《內科醫學年鑑》自 1927 年創刊以來，首次以英文、中文繁體和簡體版同時發表一篇研究類文章，說明國際醫學界對中醫藥研究的重視。試驗報告規範的制定期望可向國內外的中醫藥研究人員、同行評審員和期刊編輯等目標讀者推廣使

Led by Professor Bian Zhaoxiang, Associate Vice-President and Director of the Clinical Division of SCM, an international group of experts has recently published a recommendation for reporting clinical trials of Chinese herbal medicine formulas (CONSORT-CHM Formulas 2017).

The recommendation was published in internationally renowned *Annals of Internal Medicine*, with the English, traditional Chinese and simplified Chinese versions released online at the same time in June 2017. This was the first time since its launch in 1927 to publish three versions of a paper, testifying to the importance attached by the international medical community to Chinese medicine research. It is hoped that CONSORT-CHM Formulas 2017 would be widely adopted by target users such as Chinese medicine researchers, peers and journal editors, with a view to enhancing not only the quality of reports on clinical trials





用，切實改善中藥複方臨床試驗報告的質量以及研究的設計和實施方法等。

卞兆祥教授說：「目前已有大量關於中藥複方的臨床試驗報告發表，然而試驗報告的質量並不十分理想，這不僅降低了中醫藥的價值，亦影響對其療效和安全性的判斷，因此急需建立臨床試驗報告指引，以利不同國家的研究人員發表臨床試驗報告，擴大中醫藥的國際影響力。」

國際工作小組成員包括來自牛津大學、渥太華大學、北京中醫藥大學及四川大學等的中醫藥臨床專家、方法學家、流行病學家和醫學期刊編輯。

CONSORT—中藥複方 2017 是在 CONSORT 聲明的基礎上，加入了中醫藥的核心元素「證」和中藥複方質量控制的具體內容而制定；部份制定工作由香港醫院管理局贊助。/

of Chinese herbal medicine formulas but also the design and methodology of the trials.

Professor Bian said: “A large number of reports on clinical trials on Chinese herbal medicine formulas have been published but the quality of reporting is not entirely satisfactory. The substandard reporting not only devalues Chinese herbal medicine but also adversely affects the judgement of the efficacy and safety of Chinese medicines. There is therefore an urgent need to establish guidelines for reporting clinical trials of Chinese herbal medicine for the benefit of researchers in different parts of the world and to increase the global influence of Chinese medicine.”


The international working group comprised Chinese medicine clinical experts, methodologists, epidemiologists and a medical journal editor from the University of Oxford, University of Ottawa, Beijing University of Chinese Medicine, Sichuan University and other institutions.

The formulation of CONSORT-CHM Formulas 2017 was based on the CONSORT Statement, with the addition of the core element of Chinese medicine theory *zheng* (meaning “pattern” or “syndrome”) as well as details pertaining to quality control of Chinese herbal medicine. The development of CONSORT-CHM Formulas 2017 was partly funded by the Hospital Authority of Hong Kong. /



# 呂愛平教授與張戈教授研究團隊 研發在體靶向骨肉瘤的基因編輯遞送系統

Professor Lyu Aiping and Professor Zhang Ge's research team develops a targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma



CRISPR/Cas9 是一種新興的基因編輯技術，已被用於腫瘤的分子機制和治療靶點的研究，但是一直缺乏一種能夠在體靶向腫瘤的基因編輯的遞送系統，限制了該技術的臨床轉化。

中醫藥學院院長呂愛平教授和研究開發部主任兼教學科研部副主任張戈教授率領的研究團隊針對上述問題的癥結，努力研究並取得突破性結果，以骨肉瘤治療為研究靶點，成功研發了適配子功能化的CRISPR/Cas9 遞送系統。團隊成員包括博士後研究學人梁超博士、研究助理教授李芳菲博士和博士研究生王璐瑤。

張戈教授說：「骨肉瘤是兒童及青少年最為常見的原發性惡性骨腫瘤，目前的治療方法主要為手術與化療，但手術後五年存活率僅為 5% 至 20%。適配子（Aptamers）是一類具有三維結構的單鏈寡核苷酸，可以與特定的細胞結合，已被廣泛應用於藥物的靶向

CRISPR/Cas9 is a rising genome editing technology which holds tremendous promise for cancer treatment. However, a major bottleneck to achieve the therapeutic potential of the CRISPR/Cas9 is the lack of an *in vivo* targeted delivery system.

A research team led by Professor Lyu Aiping, Dean of SCM, and Professor Zhang Ge, Director of Technology Development Division and Associate Director of Teaching and Research Division of SCM, has achieved a breakthrough in the search for an answer to the crux of the abovementioned problem. The team has succeeded in developing an aptamer-functionalized delivery system for CRISPR/Cas9 with the treatment of osteosarcoma (OS) as a research target. Members of the SCM research team include Dr. Liang Chao, Post-doctoral Research Fellow; Dr. Li Fangfei, Research Assistant Professor; and Ms. Wang Luyao, PhD student.

Professor Zhang Ge said: "OS, a very common primary malignant bone tumor in children and adolescents, is mainly treated by surgery and chemotherapy but the five-year post-surgery survival rate is a mere



遞送。VEGFA 基因已被證實為骨肉瘤治療的潛在靶點。」

呂愛平教授說：「我們把識別腫瘤細胞的適配子作為靶向配體，與包裝了 CRISPR/Cas9 的聚合生物材料（PPC）偶聯在一起，有利於實現腫瘤內的治療性基因編輯。」

在以小鼠模型進行的實驗中，該遞送系統可加速 CRISPR/Cas9 在小鼠模型骨肉瘤和肺轉移病灶的特異性聚集，促進腫瘤細胞的 VEGFA 基因編輯，抑制腫瘤惡化，降低肺轉移，減少腫瘤組織血管增生，抑制骨破壞，並無明顯毒性。該 CRISPR/Cas9 靶向遞送系統加速了基因編輯策略在腫瘤治療領域的臨床轉化應用。

研究人員最近於生物材料範疇的國際權威雜誌 *Biomaterials* 發表題為「Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma (基於適配子功能化的腫瘤細胞特異性 CRISPR/Cas9 遞送系統實現骨肉瘤 VEGFA 基因編輯)」的研究論文 (<https://www.ncbi.nlm.nih.gov/pubmed/28938163>)。

參與該研究工作的還有浸大中醫藥學院祝海龍博士研究團隊成員王超博士和香港中文大學中醫學院張保亭教授研究團隊的張宗康博士。 /

5% to 20%. Aptamers which are single-stranded oligonucleotides and could specifically recognize target cells have been widely used for *in vivo* targeted delivery of therapeutics. VEGFA has been reported to be a novel therapeutic target for OS.”

Professor Lyu Aiping said: “The tumor-specific aptamers, when conjugated with PPC polymers encapsulating CRISPR/Cas9, may facilitate therapeutic genome editing in tumors.”

In the experiments using a mouse model, the aptamer facilitated selective distribution of CRISPR/Cas9 in both orthotopic OS and lung metastasis, leading to effective *in vivo* VEGFA genome editing, inhibited orthotopic OS malignancy and lung metastasis, as well as reduced angiogenesis and bone lesion with no detectable toxicity. The research facilitated clinical application of CRISPR/Cas9 in tumor treatment.

The researchers have published a paper entitled “Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma” in the internationally renowned journal *Biomaterials* (<https://www.ncbi.nlm.nih.gov/pubmed/28938163>).

Other researchers who participated in the research include Dr. Wang Chao from the research team of Dr. Zhu Hailong of SCM, HKBU, and Dr. Zhang Zong-Kang of the research team of Dr. Zhang Bao-Ting of the School of Chinese Medicine, The Chinese University of Hong Kong. /



# 學院成功研發特异性識別和治療腫瘤的 適配子——天然產物偶合物


## SCM scholars develop tumor-specific aptamer-drug conjugate

核仁素適配子紫杉醇偶合物作用原理圖  
A schematic diagram of the working mechanism  
of nucleolin aptamer-paclitaxel conjugate

腫瘤化療藥物的毒副作用是癌症臨床治療的嚴峻挑戰，主因是化療藥物無法區分正常細胞和癌細胞，除了破壞癌細胞也破壞正常細胞，限制了化療藥物的臨床依從性。由中醫藥學院院長呂愛平教授與技術開發部主任兼教學科研部副主任張戈教授率領的聯合研究團隊利用能夠特异性識別並靶向癌細胞的適配子來偶聯來源於植物的具有高細胞毒活性的天然產物，形成新一代的智慧型腫瘤靶向化合物，即適配子-藥物偶合物。該聯合團隊的最新研究論文“高水溶性的核仁素適配子紫杉醇偶合物靶向治療卵巢癌”最近在《自然—通訊》雜誌發表 (<https://www.nature.com/articles/s41467-017-01565-6>)。

適配子是一類具有三維結構的單鏈寡核苷酸，可以與特定的細胞及靶分子結合。由於它具有高水溶性、低免疫原性、較強的細胞穿透和穩定性，已被廣泛應用於小分子或核酸藥物的靶向遞送。目前，核仁素適配子已被證實具有良好的安全性和癌細胞識別特异性。通過將識別癌細胞的核仁素適配子與目前治療癌症的一線藥物紫杉醇化學偶聯形成一個分子，不僅可以賦予細胞毒藥物（譬如紫杉醇）的癌細胞靶向性，還可以顯著改善細胞毒藥物（譬如紫杉醇）的水溶性。該團隊開發了具有高水溶性的核仁素適配子-紫杉醇偶合物。其中連接鍵採用癌細胞酶敏感鍵，也就是在循環系統中保持穩定，在癌細胞中可以斷裂釋放細胞毒藥物（譬如紫杉醇）的原藥。研究結果表明，此偶合物在小鼠腫瘤移植模型中展現出良好的癌細胞靶向性與顯著的抗腫瘤活性，同時降低了紫杉醇的毒副作用。

參與該項研究工作的還有學院的研究助理教授李芳菲博士和三名博士後研究學人魯軍博士、劉進博士和梁超博士，以及香港中文大學醫學院張保亭教授團隊。/



Toxicity of cancer chemotherapy is a great clinical challenge, mainly due to the fact that chemo drugs cannot distinguish cancer cells from normal cells. SCM scholars devote their efforts to the development of the next generation of smart anti-cancer drug molecules: tumor-specific aptamer-drug conjugate. Their research paper entitled “A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer” has recently been published in the internationally renowned academic journal *Nature Communications* (<https://www.nature.com/articles/s41467-017-01565-6>). The research team is led by Professor Lyu Aiping, Dean of the School of Chinese Medicine (SCM), and Professor Zhang Ge, Director of Technology Development Division and Associate Director of Teaching and Research Division of SCM.


Aptamers are single strand oligonucleotides that could form 3D structures and bind to specific cell types or proteins. They have been widely used for targeted drug delivery of small molecules and siRNAs due to their advantages such as good water solubility, low immunogenicity, high permeability and stability. To date, nucleolin aptamer has been proved to be safe and tumor-specific. By conjugating nucleolin aptamer with a first line chemo drug paclitaxel into one molecule, the aptamer could improve both water solubility and tumor-targeting of the conjugated paclitaxel. The research team used an enzyme sensitive linker, and it helped the conjugate remain stable in the circulation and release paclitaxel in tumor cells. The results showed that the conjugate exhibited excellent antitumor activity and decreased toxicity.

Other researchers who participated in the research include SCM's Research Assistant Professor Dr. Li Fangfei, Post-doctoral Research Fellow Dr. Lu Jun, Post-doctoral Research Fellow Dr. Liu Jin, Post-doctoral Research Fellow Dr. Liang Chao, and the research team of Dr. Zhang Baoting of the School of Chinese Medicine, The Chinese University of Hong Kong. /



# 學院新開發的「LogicTRN」有助快速尋找複雜疾病的關鍵調控路徑及治療靶基因

“LogicTRN” newly developed by SCM  
useful for unravelling key pathways and  
new therapeutic targets of complicated diseases



中醫藥學院院長呂愛平教授、技術開發部主任兼教學科研部副主任張戈教授與教學科研部助理教授祝海龍博士共同領導的生物資訊研究組最近開發出一種新方法「LogicTRN」，用於解構多個轉錄因子在調控同一個目標基因過程中所執行的組合調控關係。該方法被成功地應用於分析雌激素誘導的乳腺癌過程及人工誘導多能幹細胞衍生的心肌細胞發育過程中的基因轉錄調控，所獲得的多個調控模式在已有的實驗中得到了很好的驗證。該項研究結果於國際著名《自然—通訊》雜誌發表 (<http://www.nature.com/articles/s41467-017-01193-0>)。


轉錄因子是一類功能蛋白，通過結合在基因啟動子區域對基因轉錄的開啟或終止進行控制。通常情況下，一個基因的表達往往受多個轉錄因子調控，這種情況在真核系統中尤為常見。多轉錄因子在調控目標基因時往往呈現出錯綜複雜的組合關係。這種複雜的組合調控是各種細胞過程的核心，也解釋了為何僅僅少量的轉錄因子（約兩千至三千個），就可以調控超過三萬個基因，使得它們在正確的細胞、正確的時間，以正確的數量進行表達。

A bioinformatics team led by Professor Lyu Aiping, Dean of SCM, Professor Zhang Ge, Director of Technology Development Division and Associate Director of Teaching and Research Division (CMTR), and Dr. Zhu Hailong, Assistant Professor of CMTR, has developed a new integrative approach “LogicTRN” to decode and characterize the logic relations among transcription factors (TFs) in regulating biological processes by combining the tTF regulatory logics and transcriptional kinetics in one model framework. “LogicTRN” was successfully applied to analyse datasets representing the estrogen-induced breast cancer and human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte (CM) development. The derived networks were consistent with existing knowledge and previous experiments. The work was published in the prestigious academic journal *Nature Communications* (<http://www.nature.com/articles/s41467-017-01193-0>).


TFs are functional proteins that can bind to the promoter of genes to turn on/off the gene expression. Usually, multiple TFs are engaged in controlling the expression of a target gene, especially in eukaryotic systems. The expression profiles of a target gene are thus the combinatorial regulatory effects of multiple TFs. This complicated and combinatorial nature of TF



A: T1-T2 stage



B: T2-T3 stage



**Fig. S2.** E2-responsible TRNs in breast cancer. For A (at T1-T2 stage) and B (at T2-T3 stage), hexagon nodes in blue are TF logics. Oval nodes refer to target genes, in red (apoptosis and p53 pathways), in green (cell cycle), in purple (cell proliferation), in orange (other cancer related pathways) and in gray (others). Logics include AND (&), NOT (¬) and OR (|).

#### 雌激素誘導的乳腺癌過程的基因轉錄調控網絡

##### E2-responsible TRNs in breast cancer

研究組目前正致力於應用計算機模型技術及大數據分析技術研究基因調控機理。呂愛平教授指出，目前科學家們正在快速積累海量的生物大數據，因此非常有必要開發有效的模型及方法，對各種生物數據進行綜合利用及分析，從而幫助理解生物過程，諸如器官發育、疾病發生及發展，以及衰老等複雜的生命過程的核心機制。張戈教授說，「LogicTRN」的開發，能夠為研究人員提供一個有效的分析工具，幫助他們快速尋找複雜疾病如癌症中的關鍵調控路徑及治療靶基因。

祝海龍博士說，「LogicTRN」是一個開放的模型框架，可以同時考慮各個細胞過程，如基因變異、蛋白-DNA結合、miRNA調控、蛋白翻譯及蛋白蛋白相互作用等對基因轉錄的調控及影響。隨著越來越多的生物過程中的數據採集和積累，基於「LogicTRN」的數據分析將可增進人類對細胞中各種分子活動的認知。

regulation is the core of various cellular processes; it also explains why the limited number of TFs (2,000-3,000) are capable of controlling the complex spatio-temporal expression of over 30,000 genes in the right cell at the right time and in the right amount throughout the life of the cell and the organism.


The bioinformatics team is currently investigating into the gene regulatory mechanisms through computational modeling techniques and big data analytics. Professor Lyu said that scientists have generated vast amount and various types of biological big data; therefore, effective computational approaches must be developed to integrate and analyse such data so as to generate useful information for understanding the biological processes that are responsible for the development of organs, progression of diseases and other complex biological events like aging. Professor Zhang Ge said that "LogicTRN" provides researchers with a powerful analytic tool in unravelling the key pathways and new therapeutic targets of complicated diseases such as cancer.

Dr. Zhu Hailong said that "LogicTRN" is an open model framework, which can be potentially extended to integrate the influences of various processes such as gene mutation, TF-DNA binding, miRNA regulation, protein translation, and protein-protein-interaction, to decode the underlying mechanisms of gene transcription. With the acquisition and accumulation of biological data of more and more cellular processes, data analysis based on "LogicTRN" can enhance a comprehensive understanding of molecular interactions in cells.



## 臨床研究顯示針灸有助控制體重

Clinical trial proves acupuncture effective for weight control



學院臨床研究初步證明針灸有助控制成人體重

SCM clinical trial offers preliminary evidence to prove that acupuncture is effective for weight control in adults.

學院與醫院管理局合作，於2015年9月至2016年10月進行臨床研究，共有72人參加，包括13男、59女，年齡介乎18至68歲，他們的BMI達25或以上，參加臨床研究前三個月內沒有接受控制體重的干預及用藥。

參加者隨機分為「真針組」及「假針組」兩個治療組別作對照研究，各人在八星期內進行共16次針灸治療，針灸穴位包括位於腹部的天樞、大橫、帶脈、氣海及中脘，以及位於小腿的足三里、豐隆及三陰交等穴位；另外也進行耳穴治療，選取耳部針對饑點、神門、脾、胃等耳穴，敷貼中藥「王不留行」。中醫認為針灸這些針灸

穴位有疏調腸腑、利水滲濕等功效。


經過針灸治療後，「真針組」參加者的體重平均減少了2.47公斤，BMI也平均下降了1.56 kg/m<sup>2</sup>。最成功的個案體重減幅達7.2公斤，BMI降低了3.2 kg/m<sup>2</sup>。「假針組」參加者的體重則只平均降低0.54公斤，BMI平均下降0.19 kg/m<sup>2</sup>。

浸大香港中醫藥臨床研究中心暨中醫藥學院臨床部主任卞兆祥教授是該項目的總負責人，成員包括臨床部講師楊君軍博士、教學科研部副教授張世平博士和臨床部研究助理教授鍾麗丹博士。

鍾博士說針灸有刺激的作用，它的機理可能是通過5-羥胺及β內啡肽（中樞神經系統和血漿），產生抑制食慾和增加脂質溶解的作用，從而令體重下降。她指出，研究結果為針灸控制體重在香港的應用提供了初步療效和安全性的證據，為未來進行大規模臨床研究和制定針灸治療肥胖臨床實踐指南奠定了基礎。/

In collaboration with the Hospital Authority, the School conducted a clinical trial on weight control from September 2015 to October 2016 involving 72 participants, comprising 13 males and 59 females aged between 18 and 68. The participants had not taken any measures nor medication for





weight control three months prior to the trial; they all had a BMI of 25 or above.

The participants were randomly assigned to two groups, i.e. the “real acupuncture group” and the “sham acupuncture group”, for the controlled trial. Each participant received a total of 16 sessions of acupuncture treatment over a period of eight weeks. Needles were applied to a number of acupoints, including *Tianshu*, *Dahen*, *Daimai*, *Qihai* and *Zhongwan* on the abdomen, and *Zusanli*, *Fenlong*, and *Sanyinjiao* on the lower limbs. In addition, auricular acupressure was used by applying *Semen Vaccariae* (*Wangbuliuxing*) to the auricular points of *Hunger*, *Shen men*, *Spleen* and *Stomach*. It is believed that applying acupuncture and moxibustion to these acupoints

can restore and harmonise the flow of energy in the intestines and organs as well as transform and expel body fluid.

The acupuncture treatment resulted in a decrease of 2.47 kg in average weight and a drop of 1.56 kg/m<sup>2</sup> in average BMI for participants in the “real acupuncture group”, with the most successful case recording a weight loss of 7.2 kg and a drop of 3.2 kg/m<sup>2</sup> in BMI. The “sham acupuncture group” recorded on average a weight loss of 0.54 kg and a drop of 0.19 kg/m<sup>2</sup> in BMI.

Professor Bian Zhaoxing, Director of HKBU Hong Kong Chinese Medicine Study Centre and Director of Clinical Division of SCM, was the principal investigator of the research team for this clinical trial; the team members included Dr. Yang Junjun,

Lecturer of Clinical Division; Dr. Zhang Shiping, Associate Professor of Teaching and Research Division; and Dr. Zhong Lidan, Research Assistant Professor of Clinical Division.

Dr. Zhong said that acupuncture had a stimulating effect. It was reckoned that acupuncture had stimulated the production of serotonin and beta endorphin which suppressed appetite and increased lipolysis activity, thereby resulting in weight loss. She explained that this trial provided preliminary evidence of the efficacy and safety of acupuncture on weight control in Hong Kong, and laid the foundation for large-scale clinical trials and for the formulation of a clinical guideline for using acupuncture to treat obesity in the future. /



# 兩項臨床觀察顯示 中醫藥治療 慢性腎衰有效

Two clinical studies find Chinese medicine effective for treating chronic renal failure

徐大基博士  
Dr. Xu Daji



## 徐大基博士臨床觀察顯示中醫藥治療慢性腎衰有效穩定率逾八成

臨床部高級講師徐大基博士分析了 162 名於 2008 年 5 月至 2016 年 12 月期間浸大中醫藥診所慢性腎衰患者病例，男女分別佔 90 例和 72 例，年齡介乎 18 至 86 歲，患病期由 3 個月至 26 年不等。所有患者均符合慢性腎衰的診斷標準，屬於慢性腎衰 1 至 3 期，即腎小球濾過率小於 80ml/min；同時並未進行腹膜透析、血液透析等治療。

根據中醫辨證論治原則，徐博士將患者歸納為不同的中醫證型，當中 43 例 (26.54%) 為脾腎虧虛及濕毒瘀阻型、30 例 (18.52%) 為脾腎氣血虧虛型，另外 22 例 (13.58%) 為濕濁困脾型，其餘 67 例為其他中醫證型。徐博士說，慢性腎衰的主要病機是脾腎虧虛、氣血不足、濕毒瘀阻，因此中醫藥治療側重於健脾補腎、益氣養血和化濕降濁。

臨床觀察結果顯示，中醫藥治療相關病患達 3 個月的有效穩定率為 96.3%，治療達半年的有效穩定率為 88.89%，治療 1 年的有效穩定率則為

83.95%。徐博士認為，中醫辨證治療有助改善患者的臨床症狀，對治療併發症或合併症等方面有顯著成效。

在觀察的病例中，部分患者病情加重的主要原因是感染，包括呼吸道感染、尿路感染、胃腸炎及皮膚感染等，合共佔 29.89%；原發病因為糖尿病、高血壓、慢性腎炎等非常多見，合共佔 69.75%，說明加強這些基礎病的早期防治，提升體質以防感染，是預防慢性腎衰惡化的有效措施。

## 蔡潯遠醫師的臨床觀察顯示「益腎化瘀泄濁法」治療慢性腎衰竭總有效率逾七成

臨床部訪問學者蔡潯遠醫師進行的臨床觀察，分析了 33 宗 2013 年 3 月至 2017 年 8 月浸大中醫藥診所慢性腎衰竭病例，病人的年齡介乎 18 至 70 歲，包括 19 男和 14 女，血肌酐小於 707umol/l，病情屬於慢性腎臟病 3 或 4 期。

蔡醫師為病人提供純中草藥處方「益腎化瘀泄濁法」治療，並一直觀察他們接受治療前後的血肌酐和腎小球濾

過率變化以及臨床症狀的改善情況。臨床觀察所見，此方對 7 人有顯著效果，17 人有效，9 人無效，總有效率為 72.7%。從臨床分期來看，此療法對 3a 期（血肌酐小於 200umol/l）病人的效果較好，20 人當中有 16 人的血肌酐在觀察期間下降，有效率達 80%，其中 5 人的血肌酐恢復到正常水平，病期由 3a 期轉為 2 期，即腎功能從失代償期恢復至代償期水平，顯示「益腎化瘀泄濁法」能改善病人的臨床症狀和延緩腎臟功能的惡化。

「益腎化瘀泄濁法」是以純中草藥為處方，主要包括淫羊藿、蟬花、丹參、川芎、大黃等，有助患者溫陽暖腎、護腎保肝、祛瘀生新和泄濁排毒。

蔡先生說，「益腎化瘀泄濁法」體現了中醫扶正與祛邪相結合，治標與治本相結合的原則。通過調理脾胃功能，降低病人的血肌酐、尿素，防止這些毒物對身體造成進一步的損害。同時增加腎小球濾過率，穩定腎臟功能，減少尿中蛋白和紅細胞；有助改善患者臨床症狀，增進食慾，強健體質，提升患者的生活質素；並延緩患者慢性腎衰的速度。/





### **Dr. Xu Daji's clinical study finds high effectiveness stability of Chinese medicine treatment for chronic renal failure**

Dr. Xu Daji, Senior Lecturer of CLNC, conducted a clinical observation of 162 patients who attended HKBU's Chinese medicine clinics for treatment of chronic renal failure from May 2008 to December 2016. The 90 male and 72 female patients, aged between 18 and 86, had been suffering from the disease for periods ranging from three months to 26 years. All patients were suffering from stage one to three of chronic renal disease, viz. they had a glomerular filtration rate below 80ml/min, and had not received hemodialysis and peritoneal dialysis.

Based on the principle of syndrome differentiation and treatment in traditional Chinese medicine (TCM), Dr. Xu classified the patients into several groups according to their different types of TCM syndromes. Of them, 43 patients (26.54%) belonged to the "spleen and kidney deficiency, damp poison and blood stasis" type, 30 patients (18.52%) were in the group of "deficiency of spleen, kidney, *qi* and blood", 22 (13.58%) were diagnosed as the "trapped spleen dampness" type, while the remaining 67 patients belonged to other syndrome types. Dr. Xu said that since the pathogenesis of chronic renal failure (CRF) was primarily caused

蔡潯遠醫師

Mr. Cai Xunyuan

by deficiency of spleen and kidney deficiency as well as *qi* and blood, damp poison and stagnation, the Chinese medicine treatment for this disease focused on invigorating the spleen and kidney, supplementing *qi* and nourishing blood as well as reducing dampness and turbidity.

The findings indicated that the rates of stability in effectiveness of Chinese medicine treatment for this disease for periods of three months, half a year and one year were 96.3%, 88.89% and 83.95% respectively. Dr. Xu said that the syndrome differentiation and treatment of Chinese medicine helped alleviate the symptoms of the patients and proved effective for dealing with related complications.

During the clinical observation, the conditions of some patients deteriorated mainly due to infection, with infection of the respiratory tract and urinary tract, gastrointestinal infection, skin infection and other infections accounting for 29.89% of the cases. As for the primary causes of CRF, a total of 69.75% of the cases were due to diabetes, high blood pressure and chronic nephritis; therefore the prevention and early treatment of these primary causes and the maintenance of a healthy body constitution were effective measures to prevent the deterioration of CRF.

### **Mr. Cai Xunyuan's clinical observation finds efficacy rate of over 70% of Chinese medicine formula for chronic renal failure**

Mr. Cai Xunyuan, Visiting Scholar of CLNC, conducted a clinical observation of 33 patients attending HKBU's Chinese medicine clinics for treatment of CRF from March 2013 to August 2017. The patients consisted of 19 male and 14 female aged between 18 and 70 who were in stage three or 4 of CRF, viz. their serum creatinine levels were less than 707umol/l.

For these patients, Mr. Cai prescribed a Chinese medicine formula which nourishes the kidney and removes

blood stasis and turbidity, and closely observed the effect of the Chinese medicine treatment on the patients' serum creatinine level, glomerular filtration rate and their clinical symptoms before and after the treatment. The observation indicated that the overall efficacy rate of the treatment for CRF was 72.7%, with seven patients showing notable improvement, 17 having general improvement while nine showed no improvement. A better therapeutic effect was observed in patients who were in the diagnosis stage of 3a (serum creatinine <200umol/l). During the observation, 16 out of 20 patients in this group recorded a decrease in their serum creatinine level with an efficacy rate of 80%, and five of them had an upturn from stage 3a to 2, meaning that their renal function had improved from the decompensatory stage to the compensatory stage. The results indicated that the Chinese medicine treatment was effective in improving the clinical symptoms of CRF patients and helped postpone the deterioration of renal function.

The prescription consists of Chinese herbs, including *Herba Epimedii*, *Isaria Cicadae*, *Radix Salviae Miltiorrhizae*, *Rhizoma Ligustici Chuanxiong* and *Radix et Rhizoma Rhei*, which work well in supplementing *yang* and warming the kidney, protecting the kidneys and liver, removing blood stasis, promoting blood regeneration, removing turbidity and detoxification.

Mr. Cai explained that the prescription embodied the Chinese medicine principles of combining the strengthening of body resistance and eliminating pathogenic factors, and tackling both the principal and subordinate symptoms. Through invigorating the spleen and kidneys, it would lower the patients' levels of serum creatinine and urea, prevent these toxins from further damaging the body, increase the glomerular filtration rate, stabilise kidney function, and reduce the protein and red blood cells in urine. It would ultimately improve the patients' conditions, resulting in a better appetite and a healthier body constitution, and slow down the progression of CRF. /



# 研究顯示 天灸治療有效改善 鼻敏感患者生活質量

Study finds *tianjiu* therapy improves allergic rhinitis patients' quality of life



醫師於病人穴位敷貼中藥研末進行天灸治療

Chinese medicine practitioner applying medicine made from powdered Chinese medicine herbs on patient's acupoints during *tianjiu* treatment.

研究團隊成員之一的臨床部研究助理教授鍾麗丹博士表示，天灸治療鼻敏感的優勢在於能調整患者的體質並有持續的效果。

Dr. Zhong Lidan, Research Assistant Professor, Clinical Division of SCM, a member of the research team, says the advantage of *tianjiu* therapy lies in its adjustment of the patients' body constitution and sustained effectiveness.

**鼻**敏感亦即過敏性鼻炎，是指免疫系統受到空氣中一些物質（過敏原）的影響而導致眼和鼻出現炎症症狀，包括流涕、鼻塞、打噴嚏、鼻癢等。在中醫學角度來說，鼻敏感是由外邪侵襲、臟腑虧虛和體質偏頗等因素引發。

天灸是其中一種傳統中醫療法，選用中藥研末敷貼在人體的穴位上，使局部皮膚充血、潮紅或起泡，以達致激發經氣、調理臟腑的治療效果。

為評估天灸療法對治療過敏性鼻炎症狀的療效與安全性，學院於2016年夏季招募了138名病人參加一項中醫天灸治療鼻敏感的隨機雙盲安慰劑對照臨床研究。參加者年齡介乎18至68歲，確診患鼻敏感兩年至45年不等。他們分為三組：天灸組、安慰劑組及對照組，每組46人。

在四星期的研究期內，天灸組、安慰劑組的參加者每星期接受一次治療，對照組的參加者則不接受任何治療。天灸組治療所用的藥含有針對鼻敏感的草藥，安慰劑組的治療則以糯米、黃豆等代替，敷貼相同的穴位。

經過四星期治療後，天灸組參加者的鼻部症狀（流涕、鼻癢、鼻塞和噴嚏）明顯較安慰劑組和對照組的參加者有改善，平均改善率達43.3%。天灸也能有效改善病人在活動和睡眠等多方面的生活質量，天灸組的改善情況較理想，總體平均改善率為22.6%。此外，在研究結束後四星期進行的隨訪反映，天灸組病人的鼻部症狀完成治療後仍然持續改善，平均改善率為39.5%。

Allergic rhinitis is inflammation of the nose resulting from over-reaction of the immune system to certain substances (allergens) in the air, thereby causing inflammation of the eyes and nose with symptoms such as runny or blocked nose, sneezing and itchy nose. From the perspective of Chinese medicine, allergic rhinitis is mainly caused by the attack of exogenous evils, deficiency of organs and an abnormal body constitution.

*Tianjiu* is a traditional Chinese medicine treatment which involves the application of a paste made from powdered Chinese medicine herbs to specific acupoints to result in hyperemia in the skin or blisters for the purpose of stimulating the meridian system and nourishing the body.

To evaluate the efficacy and safety of *tianjiu* therapy for treating allergic rhinitis, SCM

recruited in the summer of 2016 a total of 138 patients to take part in a double-blinded randomised placebo-controlled clinical trial on *tianjiu* therapy for allergic rhinitis. The participants, aged between 18 and 68, had been suffering from allergic rhinitis for two to 45 years. They were divided into three groups, with 46 persons each for the *tianjiu*, placebo and control groups.

During the four-week trial period, the participants of the *tianjiu* and placebo groups received treatment once a week while those of the control group were not given any treatment. The medicine administered to the *tianjiu* group consisted of herbs for treating allergic rhinitis while that administered to the placebo group was made from glutinous rice and soya bean and applied to the same acupoints.

After four weeks of treatment, the nasal symptoms (rhinorrhea, nasal itching, nasal obstruction, and sneezing) of the *tianjiu* group improved considerably compared to those in the placebo and control groups, with the improvement rate averaging 43.3%. *Tianjiu* treatment also enhanced patients' quality of life in terms of their activities and sleep, with an overall improvement rate of 22.6%, which was more significant than those for the other two groups. It was also found out from the follow-up survey conducted four weeks after the treatment that the nasal symptoms of the *tianjiu* group continued to improve, with the average improvement rate being 39.5%.



# 頭皮針能有效治療兒童自閉症

Scalp acupuncture effective for treating autistic children

尤傳香醫師說頭皮針能有效治療兒童自閉症  
Ms. Ann Yau says scalp acupuncture is effective for treating autistic children.



持續及專業教育部講師尤傳香醫師於2010年5月至2013年6月對68名已確診的自閉症兒童進行頭皮針治療，包括57男11女，年齡由2歲至10歲。他們每星期接受針刺治療兩次，30次為一個療程。

在68名自閉症兒童中，47人屬於「早發性自閉症」，於出生後首一至兩年已有異常的社交發展及語言遲緩症狀；21人則屬於「退行性自閉症」，他們出生後首一年半發展正常，其後漸漸失去早期已有的技能，並開始出現自閉症的症狀。

尤醫師從多種自閉症的臨床表現中挑選出五個最常見的症狀：「社交障礙」、「語言遲緩」、「行為固執」、「聲音敏感」，以及「飲食挑剔」，按各症狀的輕重程度為每名病童評分，症狀愈重，評分愈高，然後將治

療前及治療30次後的得分作統計、比較及分析。臨床觀察結果顯示，51名兒童（75%）的症狀在治療後顯著減少，15人（22%）被評為有效，另外2人（3%）則為無效，總有效率達97%。

在「原發性自閉症」組別中，病童接受治療後各項症狀的整體評分均有所下降，顯示症狀在治療後得到改善：「語言遲緩」降34.8%、「社交障礙」降37.9%、「行為固執」降27.6%、「飲食挑剔」降21.8%、「聲音敏感」降17.2%。

在早發性自閉兒童組別，病童接受治療後各項症狀的整體評分均下降：語言遲緩症狀降37.9%、社交障礙症狀降34.8%、行為固執症狀降27.6%、飲食挑剔症狀降21.8%、聲音敏感症狀降17.2%。

退行性自閉症兒童組別的整體評分也在病童接受治療後下降，依次是社交障礙的症狀降32.8%、語言遲緩症狀降31.4%、聲音敏感症狀降30.9%、行為固執症狀降23.4%、飲食挑剔症狀降21.4%。

尤醫師說，針刺療法對改善社交及語言方面的症狀，較改善行為、聲音及飲食方面的症狀明顯；兒童愈早接受針刺治療，改善症狀的機會愈大；相比之下，針刺療法對早發性自閉兒童較退行性自閉症兒童更為有效。

此外，這項臨床觀察也統計了病童及其家庭成員患過敏性疾病的比例。在早發性自閉症病童組別中，患有過敏性疾病的病童與其家庭成員的患病率一樣，均為21%；在退行性自閉症病童組別中，38%的病童患有過敏性疾病，52%的家庭成員患此病。/





一名兒童自閉症患者接受針刺治療  
An autistic child patient receives scalp acupuncture treatment.

Between May 2010 and June 2013, Ms. Ann Yau, Lecturer of the Division of Continuing and Professional Education, SCM, attended to 68 autistic patients of the HKBU Chinese medicine clinics, including 57 boys and 11 girls aged between 2 and 10. She performed on each of the patients a course of scalp acupuncture comprising 30 bi-weekly sessions over a period of 15 weeks.

Among the 68 autistic children, 47 of them were diagnosed to be suffering from “natal autism”, i.e. they had shown abnormal social development and speech delay in the first year after birth, while 21 of them were diagnosed with “regressive autism”, i.e. they had had normal development in the first 18 months after birth but had gradually lost the previously acquired skills and started to show symptoms of autism.

Ms. Yau selected five of the most common symptoms of autism as assessment criteria: impaired social interaction, delayed verbal

communication, behavioural problems, noise sensitivity and food selectivity. The young patients were given a rating for each of the symptoms before and after the treatment programme and the data were compared and analysed. The findings of the clinical observation revealed that the treatment had significant effect on 51 patients (75%) whose symptoms had been reduced significantly, was effective for 15 patients (22%) and ineffective for two patients (3%), giving rise to an overall efficacy rate of 97%.

For the group of natal autistic patients, decreases were registered in the total score of each of the symptoms: a drop of 37.9% in delayed verbal communication, 34.8% in impaired social interaction, 27.6% in behavioural problems, 21.8% in food selectivity and 17.2% in noise sensitivity.

The group of children with regressive autism also recorded decreases in the symptoms: a decrease of 32.8% in impaired social interaction, 31.4% in

delayed verbal communication, 30.9% in noise sensitivity, 23.4% in behavioural problems and 21.4% in food selectivity.

Ms. Yau said that after the treatment the patients showed more notable improvements in social interaction and verbal communication than in behaviours, noise sensitivity and food selectivity. Moreover, the earlier the children received acupuncture therapy, the higher the effectiveness. This therapy proved more effective for natal autistic patients than patients with regressive autism.

The observation also studied the percentage of patients with allergic diseases and the percentage of their family members with allergic diseases. For the group of natal autistic patients, the percentages of those with individual and family history of allergies were both 21%. For the regressive autism cases, 38% of the patients had allergic diseases while 52% of them had family members suffering from allergies. /



## 與哈佛醫學院合辦傳統中醫與西醫研討會

Joins hands with Harvard Medical School to organise traditional Chinese and Western medicine symposium



香港浸會大學與美國哈佛醫學院於6月20及21日在哈佛醫學院合辦題為「傳統中醫與西醫：我們可以從對方學到什麼」的研討會。這個兩院首次合辦的學術活動匯聚了從事西醫和中醫的臨床醫生和科學家，他們除了分享知識和進行討論，也積極尋求科研合作的機會。

浸大副校長（研究及拓展）黃偉國教授率領浸大一個20人的代表團參加研討會，代表團成員包括中醫藥學院和理學院的學者、科研人員及博士研究生，他們通過演講及海報展示，分享中醫對證候診斷及分類的智慧。

四名中醫藥學院的學者於首日舉行的公開研討會上介紹了他們在中醫藥方面的研究工作。呂愛平院長介紹了中醫治療及中醫證候分類概覽，浸大協理副校長暨臨床部主任卞兆祥教授主講中醫臨床研究的特色及挑戰，教學科研部主任李敏教授探討以中醫臨床為基礎研發保護神經藥物，技術開發部主任張戈教授分享結合西藥及中藥複方藥的藥物研發工作。哈佛醫學院的專家包括George Daley院長，Charles Serhan教授及Jon Clardy教授等也就多個範疇分享研究成果和心得，包括化學生物及天然產品的藥物研發、結合針灸療法的腫瘤治療、西醫及傳統醫學的安慰劑效用、蛋白質組學、異生素代謝、腸道微生物、訊息工具等。第二天的研討會舉行專題小組討論，來自浸大和哈佛醫學院的臨床專家和科研人員就首日的講座內容進行了深入討論，增進兩校進一步合作的契機。

中醫藥學院的專家也參觀了哈佛醫學院的附屬醫院麻省總醫院和附屬機構Dana-Farber Cancer Institute，以及哈佛大學的阿諾德植物園和自然歷史博物館，對學院的發展很有參考價值。/

HKBU joined hands with the Harvard Medical School (HMS) to organise a two-day symposium entitled “Traditional Chinese and Western medicine: what can we learn from each other” on HMS campus on 20 and 21 June. The first-ever event of its kind between the two schools brought together scientists and clinicians from western and Chinese medicine to not only share knowledge but also spark discussions and potential research collaborations.

Professor Rick Wong, Vice-President (Research and Development), HKBU, led a 20-member delegation comprising scholars, researchers and PhD students from SCM and the Faculty of Science to attend the symposium. The HKBU delegation shared their wisdom on the use of Chinese medicine approaches to diagnosis and disease classification through delivering talks and making poster presentations.

Four SCM scholars gave enlightening talks about their research on Chinese medicine at the public symposium held on the first day. While Professor Lyu Aiping, Dean of SCM, gave an “Overview of TCM therapy and TCM classification of syndromes of diseases”, Professor Bian Zhaoxiang, Associate Vice-President of HKBU and Director of Clinical Division of SCM, delivered a talk on “Characteristics and challenges for clinical trial with Chinese medicine”, Professor Li Min, Director of Teaching and Research Division of SCM, spoke on “Exploration of neuroprotective drug discovery based on TCM clinical practice”, and Professor Zhang Ge, Director of Technology Development Division of SCM, shared his work on “New drug development by combination of Western drugs and Chinese medicine compounds”. HMS experts including Dean George Daley, Professor Charles Serhan and Professor Jon Clardy also gave talks on topics including chemical biology and natural product-based drug discovery, integrating acupuncture into conventional cancer treatment, placebo effects in western and traditional medicine, proteomics, xenobiotics metabolism, gut microbiome, informatics tools, etc. Focus group discussions were held on the second day at which clinical experts and researchers from HKBU and HMS conducted in-depth discussions on the contents of the talks delivered on the first day, and explored opportunities for future collaborations.

Aside from the symposium, the SCM delegates visited the Massachusetts General Hospital and the Dana-Farber Cancer Institute affiliated to HMS, the Arnold Arboretum of Harvard University and the Harvard Museum of Natural History, and the visits proved to be very inspirational. /



## 第三屆中醫中藥發展 (香港) 論壇暨 骨與關節疾病 學術大會

3<sup>rd</sup> Forum on Development of  
TCM (HK) & Academic  
Conference on Bone and  
Joint Diseases



由香港浸會大學、國家中醫藥管理局對台港澳中醫藥交流合作中心及世界中醫藥學會聯合會骨關節疾病專業委員會攜手主辦，香港中醫骨傷學會、香港中醫學會、浸大中醫藥學院共同承辦的「第三屆中醫中藥發展（香港）論壇暨骨與關節疾病學術大會」於7月16、17日在浸大舉行。

論壇以「中醫藥治療骨關節疾病的繼承、創新與發展」為主題，吸引逾600人出席，包括內地及香港相關政府部門官員、學者、中醫中藥業界領軍人士，香港的骨與關節疾病專家，註冊中醫師，以及學院的師生、校友。

主持開幕儀式的人士包括國家中醫藥管理局國際合作司司長兼港澳台辦公室主任王笑頻司長、國家中醫藥管理局對台港澳中醫藥交流合作中心主任楊金生教授、香港食物及衛生局局長陳肇始教授、香港衛生署署長陳漢儀醫生、浸大中醫藥學院院長呂愛平教授、世界中醫藥學會聯合會副秘書長陳立新教授，以及承辦單位、協辦單位及支持單位的代表。

約30名來自內地多間中醫藥大學及中醫院的專家學者、香港的中醫骨傷專家在論壇上主講，分享他們治療骨與關節疾病積累數十年的專業知識及臨床心得，增加與會人士對這範疇的認識，進一步促進中醫藥在香港的發展。/

The 3rd Forum on Development of TCM (Hong Kong) & Academic Conference on Bone and Joint Diseases, co-organised by HKBU; Taiwan, Hong Kong and Macao Chinese Medicine Exchange and Cooperation Centre, State Administration of Traditional Chinese Medicine (SATCM) of PRC; and the Specialty Committee of Bone and Joint Diseases of World Federation of Chinese Medicine Societies (WFCMS); was held on HKBU campus on 16 and 17 July. The Forum was co-hosted by The Hong Kong TCM Orthopaedic and Traumatic Association, Hong Kong Association of Traditional Chinese Medicine and SCM of HKBU.

Carrying the theme “Chinese medicine treatment for bone and joint diseases: inheritance, innovation and development”, the forum attracted more than 600 participants comprising government officials, scholars and leading figures in the Chinese medicine sector from the Chinese mainland and Hong Kong, local experts in bone and joint diseases, registered Chinese medicine practitioners as well as faculty members, students and alumni of SCM.

The officiating party comprised Ms. Wang Xiaopin, Director of Department of International Cooperation (Hong Kong, Macao and Taiwan Affairs Office), SATCM; Professor Yang Jinsheng, Director of Taiwan, Hong Kong and Macao Chinese Medicine Exchange and Cooperation Centre, SATCM; Professor Sophia Chan, Secretary for Food and Health, HKSAR Government; Dr. Constance Chan, Director of Health, HKSAR Government; Professor Lyu Aiping, Dean of SCM, HKBU; Professor Chen Lixin, Vice Secretary-General, WFCMS; as well as representatives of the co-organisers and support organisations.

At the forum, close to 30 experts from universities of Chinese medicine and Chinese medicine hospitals on the mainland as well as local Chinese medicine experts in bone and joint diseases delivered inspiring talks and shared their wealth of clinical knowledge and experience accumulated over decades to enlighten the audience and further promote the development of Chinese medicine in Hong Kong. /



## 中藥質量研究及標準化論壇

### Forum on Quality Research and Standardisation of Chinese Medicines

學院於 8 月 24 日及 25 日承辦由國家自然科學基金委員會、京港學術交流中心及浸大攜手合辦的中藥質量研究及標準化論壇。論壇邀得 21 名內地、澳門和香港的專家學者主講，與出席論壇的中藥專家學者和企業代表就中藥質量研究及標準化進行交流分享。

出席論壇的專家就論壇的三個專題，即基礎研究、中成藥的基礎與臨床研究及研究方法學，作主題報告，與出席人士深入探討相關課題，旨在集思廣益，促進香港與澳門和內地高校及研究機構的相互交流合作，為中藥標準化和中藥科技創新作出貢獻。

論壇開幕典禮的主禮人包括香港浸會大學校長錢大康教授及中醫藥學院院長呂愛平教授、國家自然科學基金委員會醫學科學部醫學科學十處張鳳珠處長及港澳台辦公室王文澤副主任、中央政府駐香港特區聯絡辦公室教育科技部副巡視員張總明先生、京港學術交流中心學術與培訓部主任鄒重華博士。

呂愛平教授在致歡迎辭時說，中藥質量是中醫藥界和市民大眾都非常關心的問題，而隨著中醫藥在全世界迅速傳播及內地經濟的急速發展，中藥出口卻有待提高，此情況反映中藥產品應積極提高在國際的競爭力。他認為中醫藥要進一步發揚光大，在兩岸三地以至世界各地的醫療體系發揮更大作用，中藥標準化和中藥質量控制是關鍵所在。呂教授相信內地於今年 7 月 1 日實施《中醫藥法》後，中醫藥的地位、發展方針和扶持措施獲得確立，中醫藥有了更好的發展台階，他期望是次論壇可以在這有利的環境下進一步促進中藥研究的長足發展。 /



SCM hosted on 24 and 25 August the Forum on Quality Research and Standardisation of Chinese Medicines jointly organised by the National Natural Science Foundation of China (NSFC), Beijing-Hong Kong Academic Exchange Centre and HKBU. A total of 21 experts and scholars from mainland China, Macao and Hong Kong gathered on campus to share their knowledge and insights on quality research and standardisation of Chinese medicines.

The experts attending the Forum delivered talks on the three themes of the forum, namely basic research, basic and clinical research of proprietary Chinese medicine, and research methodology, and had in-depth discussions with the participants, with a view to generating collective wisdom and fostering collaboration among academic institutions and research institutes in Hong Kong, Macao and mainland China and contributing to the standardisation of Chinese medicines and innovation in Chinese medicines science and technology.

The opening ceremony of the Forum was officiated by Professor Roland Chin, President and Vice-Chancellor of HKBU; Professor Lyu Aiping, Dean of School of Chinese Medicine, HKBU; Ms. Zhang Fengzhu, Director of Division Ten of Health Sciences, Department of Health Sciences, NSFC; Mr. Wang Wenzhe, Deputy Director of Hong Kong, Macao and Taiwan Affairs Office, NSFC; Mr. Zhang Zongming, Deputy Inspector of Education, Science and Technology Department, Liaison Office of the Central People's Government in HKSAR; and Dr. Zou Chonghua, Head of Division of Academic and Training, Beijing-Hong Kong Academic Exchange Centre.

In his welcoming remarks, Professor Lyu Aiping said that the quality of Chinese medicines was a major concern among both Chinese medicine professionals and the general public. Moreover, despite the increasing popularity of Chinese medicine throughout the world and China's rapid economic growth, the export of Chinese medicines was not entirely unsatisfactory and this pointed to the need to enhance the competitiveness of Chinese medicine products. He pointed out that the standardisation and quality control of Chinese medicines were keys to the robust development of Chinese medicine and to the strengthening of its role in the healthcare systems in the country as well as other parts of the world. With China's implementation on 1 July 2017 of the Chinese Medicine Ordinance which spells out the role of as well as policies and support measures for Chinese medicine, Professor Lyu believed that Chinese medicine now enjoyed a better development platform and hoped that the Forum would contribute to research on Chinese medicines under such favourable conditions. /



## 王國強副主任 闡述中國新實施的 中醫藥法的影響

Mr. Wang Guoqiang  
expounds the impact of  
the country's new law  
on traditional Chinese  
medicine



《中華人民共和國中醫藥法》（簡稱《中醫藥法》）由全國人民代表大會常務委員會於 2016 年 12 月 25 日通過，自今年 7 月 1 日起施行。

學院與香港浸會大學創意研究院於 9 月 24 合辦傑出學人講座，由國家衛生和計劃生育委員會副主任、國家中醫藥管理局局長王國強介紹「新實施的中國首部中醫藥法對中醫藥發展的影響」，吸引約 180 名衛生署官員、中醫藥業界人士、中醫藥師生、校友、註冊中醫師參加，瞭解中醫藥法對他們的影響和國家的第一套中醫藥法規將如何推動中醫藥的發展。講座由孔憲紹慈善基金贊助。

王副主任說，中央政府從經濟社會發展全域、健康中國建設大局著眼，提出了一系列發展中醫藥的新思想、新論斷和新要求，對中醫藥的發展作出了新規劃和戰略部署，並首次從法律層面明確了中醫藥的重要地位、發展方針和扶持措施，將中醫藥的醫療、保健、教育、科研、產業、文化及國際交流等納入法律框架下，是中醫藥行業實行依法治理的重要依據，對於促進中醫藥治理體系和治理能力現代化、保障中醫藥振興發展、維護人民健康福祉具有劃時代意義。王副主任說，《中醫藥法》的出台對繼承和弘揚中醫藥及促進中醫藥事業的健康發展具有重要意義。

王副主任闡述《中醫藥法》涵蓋的要點，包括界定中醫藥服務、中藥保護與發展、中醫藥人才培訓、中醫藥科學研究、中醫藥傳承與文化傳播、法治保障等。/

The Law of the People's Republic of China on Traditional Chinese Medicine which was passed by the National People's Congress of the People's Republic of China on 25 December 2016 came into effect on 1 July 2017.

In collaboration with the Institute of Creativity of HKBU, SCM hosted on 24 September a Distinguished Lecture featuring Mr. Wang Guoqiang, Vice Minister of National Health and Family Planning Commission and Commissioner of State Administration of Traditional Chinese Medicine, who spoke on "Impact of the Country's First Law on Traditional Chinese Medicine on the Development of Chinese Medicine". An audience of about 180 comprising officials from the Department of Health, professionals from the Chinese medicine industry, teachers, students and alumni of SCM and other local universities as well as registered Chinese medicine practitioners attended the Lecture to gain a better understanding of the impact of the new legislation and how it would foster the development of Chinese medicine. The Lecture was sponsored by the Hung Hin Shiu Charitable Foundation.

Mr. Wang said that the central government had from the broad perspectives of the socio-economic development of the country and the goal of building a healthy country put forward a series of new ideas, judgements and demands, and made new plans and strategies for the development of Chinese medicine. Consequently legislation had been enacted for the first time to set out the significant role and development direction of as well as support measures for Chinese medicine, and to regulate different aspects of Chinese medicine, including medical service, healthcare, education, research, industry, culture and international exchange, and the new law was now an important basis for the regulation of the Chinese medicine industry, and was all-important in modernizing and enhancing the governance of Chinese medicine, fostering the robust development of Chinese medicine and contributing to public health. Mr. Wang said that the enactment and implementation of the Chinese medicine law was of great significance to the inheritance and advancement of Chinese medicine as well as the promotion of the healthy development of the Chinese medicine industry.

Mr. Wang elucidated the main provisions of the Chinese medicine law, which covered the areas of Chinese medicine services, protection and development of Chinese materia medica, nurturing of Chinese medicine professionals, scientific research, inheritance and promotion as well as protection by the rule of law. /



## 「一帶一路」開啟 中醫藥國際化新篇章

Belt and Road Initiative:  
a new era of  
internationalisation of  
Chinese medicine

學院於 10 月 21 日舉辦香港浸會大學「一帶一路」公開講座，由中國工程院院士、中國中醫科學院常務副院長黃璐琦教授主講「『一帶一路』開啟中醫藥國際化新篇章」。由於黃教授未能來港，由學院副院長趙中振教授介紹其演講內容。講座主題環繞作為中國傳統優勢資源的中醫藥近年在內地發展迅速，除了中醫藥研究取得顯著成績，中醫藥學學科發展也面臨重大機遇，但同時也有諸多制約與挑戰，如中醫藥發展的資源依賴性、中醫藥的效果尚未得到多數國家的立法認可、中醫藥的標準體系受制於外以致未能發揮自身的優勢特色等，這些都要通過大型的國際合作研究計劃來推動解決。 /



SCM hosted a lecture on “Belt and Road Initiative: a new era of internationalisation of Chinese medicine” on 21 October under the University's Belt and Road Public Lecture and Concert Series. Since the speaker Professor Huang Luqi, Academician of Chinese Academy of Engineering and Executive Vice President of China Academy of Chinese Medical Sciences, was unable to come to Hong Kong, Professor Zhao Zhongzhen, Associate Dean of SCM delivered the lecture on his behalf. The Lecture discussed traditional Chinese medicine as a precious resource of China and the remarkable achievements made in Chinese medicine research in recent years. While there have been substantial achievements in scientific research in Chinese medicine and ample opportunities have emerged for the development of Chinese medicine as an academic discipline, there are at the same time many constraints and challenges, such as resource dependence in the development of Chinese medicine, the fact that Chinese medicine has not been officially recognised by a large number of countries, and the situation where the standardisation of Chinese medicine is subject to external factors, thereby rendering it difficult to bring the advantages and characteristics of Chinese medicine into full play. To solve these problems, large-scale international cooperation research programmes are called for. /

## 程京院士主講中西醫 並重的疾病測調診治

Professor Cheng Jing lectures  
on “Use of both TCM and  
Western medicine in diagnosis  
and treatment of diseases”

學院與浸大創意研究院於 5 月 25 日合辦的傑出學人講座，邀得中國工程院院士、清華大學醫學院生物醫學工程系及醫學系統生物學研究中心教授程京教授擔任講者，發表題為「中西醫並重的疾病測調診治」的演講。程教授認為，中西醫的技術和手法可以有效地組合後應用於疾病的檢測、調理、診斷和治療，對於慢性病效果尤佳。他介紹其團隊如何應用中西醫學及現代工程技術研發多項醫療產品，包括開發一套能顯示病人患病徵兆的眼像分析系統，方便醫生跟進作出診斷和治療。 /



The Distinguished Lecture jointly organised by SCM and the Institute of Creativity of HKBU on 25 May featured Professor Cheng Jing, Academician of Chinese Academy of Engineering, and Professor of Medical Systems Biology Research Center and Department of Biomedical Engineering, School of Medicine, Tsinghua University. In his talk about the use of both TCM and Western medicine in diagnosis and treatment of diseases, Professor said that the techniques and methodology of Chinese and Western medicine could be integrated and effectively applied to the examination, diagnosis and treatment of diseases, particularly chronic diseases. He introduced to the audience how his research team had integrated Chinese and Western medicine with modern engineering technology to develop a number of medical products, including an eye pattern analysis system which would reveal disease symptoms for diagnosis and treatment by doctors. /



## 卞兆祥教授獲頒授「曾肇添中醫藥 臨床研究講座教授」榮銜

Professor Bian Zhaoxiang conferred  
the title of Tsang Shiu Tim Endowed Chair of  
Chinese Medicine Clinical Studies



協理副校長（中醫藥發展）及臨床部主任卞兆祥教授獲浸大頒授「曾肇添中醫藥臨床研究講座教授」榮銜，表揚他在臨床研究方面的傑出表現。大學於11月1日舉行「冠名講座教授就職典禮2017」，由浸大校董會暨諮議會主席鄭恩基先生和校長錢大康教授主禮。冠名講座教授席是浸大授予校內傑出學者的其中一項最崇高榮譽。

Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development), and Director of Clinical Division, SCM, was conferred the title of Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies for his outstanding achievements in clinical studies. The Inauguration Ceremony of Endowed Chairs 2017, officiated by Mr. Cheng Yan-kee, Chairman of the Council and the Court of HKBU, and Professor Roland Chin, President and Vice-Chancellor of HKBU, was held on 1 November. An Endowed Chair is one of the highest honours to be bestowed upon prominent academics by the University. /

## 趙中振教授獲安徽中醫藥大學 聘為客座教授

Professor Zhao Zhongzhen  
appointed visiting professor of Anhui University of  
Traditional Chinese Medicine



副院長趙中振教授最近獲安徽中醫藥大學任命為客座教授。趙教授於9月11日在該校舉行的儀式上從校長彭代銀教授手上接過聘書，並於儀式上把他的最新著作《中振說本草》送贈給該校，接著發表題為「本草世界」的報告。

Professor Zhao Zhongzhen, Associate Dean of SCM, was conferred visiting professorship by the Anhui University of Traditional Chinese Medicine (AHUTCM). At the conferment ceremony held on AHUTCM campus on 11 September, Professor Zhao received the appointment certificate from Professor Peng Daiying, Vice-President of AHUTCM, and presented to AHUTCM his latest publication 《中振說本草》, following which he delivered a talk entitled "The World of Materia Medica". /

## 呂愛平教授獲 香港中藥業協會 頒發中藥科研貢獻獎

Professor Lyu Aiping receives award  
from Hong Kong Chinese Medicine  
Industry Association for contribution  
to Chinese medicine research

呂愛平院長獲香港中藥業協會頒發中藥科研貢獻獎，表彰他對中藥科研工作的傑出成就和重大貢獻。香港特區政府衛生署署長陳漢儀醫生在9月1日舉行的頒獎



典禮上把獎狀授予呂教授。呂教授認為中藥研究的發展空間廣闊，也樂見中藥業界與學界緊密合作，共同提升中藥質量和安全水平。

Professor Lyu Aiping, Dean of SCM, was conferred the Award for Contribution to Chinese Medicines Research by the Hong Kong Chinese Medicine Industry Association for his outstanding achievements and important contribution to Chinese medicines research. He received the award from Dr. Constance Chan, Director of Health, HKSAR Government, at a ceremony held on 1 September. Professor Lyu believes there are broad prospects for advancing Chinese medicines research, and is gratified to see close collaboration between the Chinese medicines industry and academia in raising the quality and safety of Chinese medicines. /



## 李敏教授研究團隊獲最佳海報獎

Professor Li Min's research team wins Best Poster Award



教學科研部主任李敏教授與她的研究團隊參加於9月3至5日在大連舉行的第一屆國際細胞自噬會議，團隊成員楊傳彬博士題為「NRBF2 通過自噬調節阿爾茨海默病模型中 APP C 末端片段 (APP-CTFs) 的降解」的研究海報獲得「最佳海報獎」，為三篇最佳海報之一。該項研究是李教授團隊與澳門大學路嘉宏博士課題組的合作項目。

Professor Li Min, Director of Teaching and Research Division (CMTR), and her research team attended the 1<sup>st</sup> National Congress of Autophagy held in Dalian, China on 3-5 September, and the poster on the research entitled "NRBF2 is involved in the degradation process of APP-CTFs in Alzheimer disease

models" presented by team member Dr. Yang Chuanbin won the Best Poster Award; it was one of the three posters to win the Award. The research project was jointly conducted by Professor Li's team and Dr. Lu Jiahong's team from the University of Macau. /

## 浸大中醫藥博物館舉辦「文樹德教授珍藏中醫藥文物展」

HKBU Museum of Chinese Medicine stages exhibition of Professor Paul U. Unschuld's collection of valuable Chinese medicine artifacts



學院於10月10日在孔憲紹博士伉儷中醫藥博物館展開為期四個月的「文樹德教授珍藏中醫藥文物展」，展出著名德國漢學家、醫史專家文樹德教授40年來珍藏的一批中醫藥文物，包括針灸掛圖、藥方、藥店牌匾、藥罐等。該批珍貴文物於香港展覽後將運往美國等地作巡迴展覽，弘揚中醫藥文化。

SCM kicked off on 10 October a four-month exhibition of Professor Paul U. Unschuld's valuable collection of Chinese medicine artifacts at the Dr. & Mrs. Hung Hin Shiu Museum of Chinese Medicine. Collected by Professor Unschuld, famous German sinologist and medical historian,

over four decades, the artifacts included acupuncture illustrations, herbal formulas, herbal shop signs and decocting vessels. After on display on HKBU campus, the collection will be exhibited in different parts of the United States to promote the culture of Chinese medicine. /



## 學院參與香港特別行政區成立 20 周年慶祝活動 SCM participates in activities to celebrate the 20<sup>th</sup> anniversary of HKSAR



為慶祝特區成立 20 周年，香港特區政府於 7 月 2 日舉辦「文物時尚·荷李活道」街頭嘉年華會。學院於嘉年華會設置「香港浸會大學中醫藥學院—雷生春堂」攤位，讓公眾人士向學院的中醫師諮詢健康意見及免費品嚐涼茶。活動獲常務副校長麥建成教授、副校長（研究及拓展）黃偉國教授、副校長（教與學）周偉立博士及署理副校長暨秘書長林朗秋先生親自到場支持及協助派發涼茶。

同日，中央電視台《焦點訪談》節目播放一輯香港故事，節目訪問了學院羅守輝骨與關節疾病轉化醫學研究所副所長張戈教授及其研究團隊，介紹團隊在中國首艘貨運飛船「天舟一號」進行關於「在太空微重力環境中「CKIP-1」基因對成骨細胞分化的影響」研究項目的實驗。

此外，團隊的研究人員梁超博士、王璐瑤女士及支援人員陳志良先生及張若韶女士喜獲香港青年聯會邀請參加由該會及香港各界慶典委員會於 6 月 30 日晚上在香港體育館舉辦的「『青蔥再出發』香港青年音樂節 2017」，在台上與中國航太員楊利偉、景海鵬及陳東交流並致送紀念品給他們。

To celebrate the 20<sup>th</sup> anniversary of HKSAR, the HKSAR Government organised on 2 July a street carnival entitled "Heritage Vogue•Hollywood Road", at which a "Hong Kong Baptist University School of Chinese Medicine Lui Seng Chun" stall was set up by the School of Chinese Medicine (SCM) to provide health

advice and herbal tea to the public for free. To show their support for the efforts of SCM, Professor Clayton Mackenzie, Provost, Professor Rick Wong, Vice-President (Research and Development), Dr. Albert Chau, Vice-President (Teaching and Learning), and Mr. Lam Long-chau, Acting Vice-President (Administration) and Secretary, went to the carnival and helped give out herbal tea to the carnival goers.

On the same day, the programme "Focus Report" of China Central Television (CCTV) broadcast an episode of *Hong Kong stories* introducing SCM's research project to investigate the effect of the "CKIP-1" gene on bone formation under microgravity conditions in space conducted on board Tianzhou-1, China's first cargo spacecraft. The programme featured an interview with Professor Zhang Ge, Associate Director of Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), and members of his research team.

In addition, upon the invitation of the Hong Kong United Youth Association, research team members Dr. Liang Chao and Ms. Wang Luyao and support staff Mr. Chan Chi-leung and Ms. Hilda Cheung attended the Hong Kong Youth Music Festival 2017 held in the Hong Kong Coliseum on 30 June. At the event jointly organised by the Association and Hong Kong Celebrations Association, they were honoured and thrilled to meet China's astronauts Mr. Yang Liwei, Mr. Jing Haipeng and Mr. Chen Dong on stage and presented souvenirs to them. /



## 學院於創新科技嘉年華展示 「中醫藥與智慧生活」

SCM promotes “Chinese Medicine and Smart Living”  
at InnoCarnival



學院參加由創新科技署於 10 月 21 至 29 日在科學園舉辦的創新科技嘉年華，今年學院以「中醫藥與智慧生活」為主題，介紹多項中醫藥養生資訊，如飲食養生、運動養生和穴位養生，並透過電腦科技，包括經絡按摩資訊系統、太極體感遊戲、「香港中醫藥文化十景」手機應用程式、虛擬實景遊戲等，讓市民體驗豐富多彩的中醫藥文化。此外，學院的資深中醫師主持講座，向公眾人士介紹中醫藥防治疾病的知識。是次展覽獲得創新及科技基金資助和北京同仁堂國藥有限公司贊助參展。

SCM staged an exhibition carrying the theme “Chinese Medicine and Smart Living” at InnoCarnival organised by the Innovation and Technology

Commission at the Science Park from 21 to 29 October. The exhibition introduced ways and means to stay healthy with Chinese medicine, including healthy eating and exercises and acupoints for good health. There were also a number of interactive edutainment activities to provide the exhibition-goers with a rich Chinese medicine cultural experience; they included a Chinese medicine acupoint massage learning software, a *tai chi* somatosensory game, a mobile app that introduced 10 local Chinese medicine cultural attractions, and a virtual reality game. Experienced Chinese medicine practitioners of SCM also gave talks on the use of Chinese medicine to prevent and treat diseases. The exhibition was funded by the Innovation and Technology Fund and sponsored by Beijing Tong Ren Tang Chinese Medicine Company Limited. /

## 冠中地產有限公司捐款支持中醫藥研究

Capital Estate Limited donates to support Chinese medicine research



冠中地產有限公司黎堅克先生和鄧楓先生慷慨捐資港幣 200 萬元，支持學院進行「基於臨床常用有效複方的治療類風濕關節炎組合藥物研究開發」。大學於 10 月 11 日舉行儀式，由錢大康校長接受捐款並感謝黎先生和鄧先生對大學的襄助。

Mr. Lai Kin-hak and Mr. Tang Fung of Capital Estate Limited made a generous donation of HK\$2 million to support the School's research project entitled “Combinational Drug Discovery from Chinese Medicines for the Treatment of Rheumatoid Arthritis”. At the ceremony held on 11 October,

Professor Roland Chin, President and Vice-Chancellor, received the donation and expressed sincere gratitude to Mr. Lai and Mr. Tang for their generosity. /



## 陳守仁基金會捐款成立 贈醫施藥中醫義診日永久基金

Tan Siu Lin Foundation funds Perpetual Fund for Free Chinese Medicine Consultation Day project



陳守仁基金會捐款港幣 100 萬元設立「陳守仁基金會贈醫施藥義診日永久基金」，資助學院舉辦義診日，免費為有需要的低收入人士提供中醫醫療服務。大學於 2016 年 12 月 2 日舉行捐贈儀式，由陳守仁基金會主席及聯泰國際集團創辦人兼主席陳守仁博士及浸大校長錢大康教授主禮。

The Tan Siu Lin Foundation has made a generous donation of HK\$1 million for the establishment of the "Tan Siu Lin Foundation Perpetual Fund for the Free Chinese Medicine Consultation Day" project. With the support provided by the fund, SCM will organise free Chinese medicine consultation days for the underprivileged. The University organised on 2 December 2016 a donation ceremony which was officiated by Dr. Tan Siu-lin, Chairman of Tan Siu Lin Foundation and Founder and Chairman of Luen Thai International Group Limited, and President Roland Chin of HKBU. /

## 學院獲捐款組建 四季食療養生數據庫

SCM receives donation to develop a database for seasonal food therapy



學院獲小盆景口味堂酒店管理有限公司捐贈 20 萬港元，支持教學科研部副教授張世平博士負責的「四季食療養生數據庫的組建」項目，該數據庫的建立將為中醫食療手機應用程式的研發奠定基礎。捐款儀式在 7 月 12 日舉行。

SCM received a donation of HK\$200,000 from Xiao Pen Jing Kou Wei Tang Hotel Management Pty Limited to develop a database for seasonal food therapy, a project of Dr. Zhang Shiping, Associate Professor of Teaching and Research Division. The database will pave the way for the future development of a mobile phone application for Chinese medicine food therapy. The donation ceremony was held on 12 July. /

## 學院集思會 2017 SCM Retreat 2017

在呂愛平院長及趙中振副院長的帶領下，約 50 名來自學院四個部門的教職員於 6 月 8 至 10 日在惠州舉行集思會，黃偉國副校長（研究及拓展）也撥冗參加，為學院的發展給予指導及寶貴意見。呂院長與參加者分享學院面對的四個主要挑戰—如何改進本科教育，讓本科生畢業後可以應付多元化的發展；如何在教學及研究之間取得平衡；學院和中醫藥的國際化；以及學院的發展策略和計劃。黃副校長表示學院近年發展迅速，值得讚揚；他勉勵學院繼續配合大學的發展策略，推進學院和中醫藥的發展。



Led by Dean Lyu Aiping and Associate Dean Zhao Zhongzhen, about 50 teaching and administrative staff of SCM went to Huizhou for a retreat from 8 to 10 June. Professor Rick Wong, Vice-President (Research & Development), joined the retreat and provided guidance and advice for the School. Professor Lyu invited participants to ponder and discuss four major challenges facing the School—the enhancement of the undergraduate programmes to better prepare the students for diversified development upon graduation, the attainment of the right balance between teaching and research, the internationalisation of SCM and Chinese medicine, and the future direction and development of SCM. Professor Wong commended the School for its rapid growth in recent years; he also encouraged faculty and staff to follow the strategies of the University and foster the development of SCM and the advancement of Chinese medicine.



## 本科生入學資訊日

Information Days for  
Undergraduate Admission



學院及大學分別於 6 月 12 日及 10 月 7 日舉辦本科生入學資訊日，學院於兩個資訊日向參加的中學生、家長及教師介紹中醫學學士及生物醫學理學士（榮譽）學位課程及中藥學學士（榮譽）學位課程的特色和入學資格，也安排校友分享他們的學習經驗和介紹學生畢業後的就業前景。此外，學院也參與了大學於五月舉行的三場聯招講座，讓本地學校學生及家長更了解上述兩個課程的特色及選科策略。

While SCM organised an Information Day for undergraduate admission on 21 June, the University also organised one on 7 October. On both occasions, SCM provided prospective undergraduates and their parents as well as teachers with information on the characteristics and admission requirements of the Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Sciences (BCM) and Bachelor of Pharmacy (Hons) in Chinese Medicine (BPharm) programmes. SCM alumni shared with the visitors their study experiences at the School and introduced the career prospects of SCM graduates. In addition, SCM participated in three sessions of Joint University Programme Admissions Scheme (JUPAS) Talk organised by the University in May to enable local school students and their parents to have a better understanding of the characteristics of the programmes and the strategies for programme selection. /

## 學院大樓獲節能比賽 「卓越慳神獎」

SCM Building wins outstanding  
award in Energy Saving  
Championship Scheme

浸大於機電工程署舉辦的「慳神大比拼 2016」專上教育院校組別比賽中，以賽馬會中醫藥學院大樓的節能效益榮獲「卓越慳神獎」。學院大樓自 2013 年進行維修工程，其中包括增設節約能源設施，這些設施共節省電力超過 450,000 度，等於 90 個香港家庭一年的電力消耗量。

## 中學生體驗學院學習生活

Secondary school students experience  
study life at SCM



學院於 7 月 20 及 25 日舉辦兩場生活體驗日營，讓參加的中學生通過課堂、模擬實驗、遊戲、參觀學院教學設施及中醫藥學生和校友的分享，了解在學院學習的情況，並鼓勵他們日後報讀學院開辦的中醫藥課程。

SCM organised on 20 and 25 July two rounds of summer exploration day camp for secondary school students. Through lectures, mock experiments, games, tour of the teaching and learning facilities at SCM, and sharing by SCM students and alumni, the students sampled study life at SCM and were encouraged to pursue programmes offered by the School. /

## 2017-18 學年兼讀制課程簡介會

Briefing session on part-time programmes

持續及專業教育部於 7 月 8 日舉辦兼讀制課程簡介會，向有興趣報讀的人士介紹該部開辦各類文憑及證書課程的教學內容、特色和報讀程序，並於簡介後即席由教學人員進行教學示範，讓出席人士感受中醫藥課堂情況。

The Division of Continuing and Professional Education hosted a briefing session on 8 July to introduce the curricula and admission requirements of its diploma and certificate programmes. The briefing was followed by classroom teaching demonstration, which enabled the participants to experience teaching and learning in the classroom. /



HKBU won the Hanson Outstanding Award in the Post-secondary Education Institution Category of the Energy Saving Championship Scheme 2016 for its energy saving project for the Jockey Club SCM Building. Renovations of the SCM Building including the installation of a number of energy-saving equipment, which started in 2013, resulted in the saving of over 450,000 kWh of energy, equivalent to the total electricity consumption of around 90 Hong Kong households for one year. /



## 學院開學禮

### SCM Convocations

學院於9月1日及2日分別為本科課程學生及碩士和其他課程學生舉行開學禮和迎新會，由院長及課程主任致辭歡迎新生加入學院，勉勵學生立志向學。本科生的開學禮邀得兩位中醫校友楊明霞和陳海勇及中藥校友簡宏良分享學習中醫藥知識的心得和就業經驗，他們鼓勵學弟妹努力裝備自己，面對畢業後的挑戰。開學禮以新生宣讀中醫藥學生約章結束。

SCM organised a convocation for the new undergraduate cohorts on 1 September and a convocation for new students of the taught master's and other programmes on 2 September. In their welcoming remarks, Dean and programme directors encouraged the new students to devote to their studies. At the convocation for the freshmen, Yeung Ming Ha and Chen Hai Yong, alumni of the Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science (BCM) programme and alumnus Kan Wang Leung of the Bachelor of Pharmacy (Hons) in Chinese Medicine (BPharm) programme shared their learning and work experiences with the freshmen and encouraged them to equip themselves and prepare for the future challenges ahead. The occasion concluded with the reciting of the student charter by the new students. /




## 2017-18 學年

### 本科收生成績理想

#### 2017-18 undergraduate admission

在學院的努力下，學院中醫學學士及生物醫學理學士（榮譽）學位課程（中醫）的聯招新生入學平均成績，於2017-18學年連續第五年成為浸大收生成績最佳的課程，而中藥學學士（榮譽）學位課程的新生平均入學成績也躍升為全校第6名。As a result of its hard work and efforts made, SCM has once again achieved good admission scores in the 2017-18 academic year. While the average HKDSE admission score of BCM is the highest in the University for the fifth consecutive year, that of BPharm ranks sixth. /



### 中醫藥學院博士生魯軍獲「挑戰杯」 全國大學生課外學術科技作品競賽一等獎

PhD student LU Jun of School of Chinese Medicine won first prize in the "Challenge Cup" National College Students' Extracurricular Academic Science and Technology Works Contest

學院博士研究生魯軍同學憑作品「一種具有良好水溶性，酶敏感性，腫瘤靶向性的智慧型抗乳腺癌藥物 - 適配子 - 紫杉醇偶合物」於第15屆「挑戰杯」全國大學生課外學術科技作品競賽決賽榮獲一等獎。本屆「挑戰杯」共有2000多所高校逾3萬個科技創新作品參加競賽，經初賽及複賽後，共有1230個作品進入決賽，其中755件作品入圍參加本年11月14至19日在上海大學舉行的終審決賽現場問辯。「挑戰杯」被譽為當代大學生科技創新的「奧林匹克」

盛會，本屆共有一等獎作品102件。PhD student Lu Jun won First Prize in the Fifteenth "Challenge Cup" National College Students' Extracurricular Academic Science and Technology Works Contest with his project entitled "Develop a Highly Water Soluble Nucleolin Aptamer Paclitaxel Conjugate with a Cathepsin Labile Linker for Tumor Specific Targeting in breast Cancer". Contestants from more than 2,000 higher education institutions submitted over 30,000 scientific and technological innovation projects in this year's "Challenge Cup". After the first and second rounds of the Contest, 1,230 projects entered the final, out of which 755 projects were selected for oral defence at the grand final held in Shanghai University from 14 to 19 November 2017. Dubbed the Olympic for college students' science and technology innovation, 102 projects were awarded First Prize in this year's "Challenge Cup". /



## 三支博士研究生隊伍獲香港大學生創新及創業大賽三獎項

### Three PhD student teams scoop 3 prizes at Hong Kong University Student Innovation and Entrepreneurship Competition

五名博士研究生組成三支隊伍參加 5 月 22、23 日在香港科學園舉行的「挑戰杯」全國賽香港區選拔賽——香港大學生創新及創業大賽，合共贏得兩個二等獎及一個三等獎。潘文慧同學和夏一璇同學憑藉「天然美肌——中藥美膚產品開發」項目，獲得初創企業作品二等獎。魯軍同學撰寫題為「一種具有良好水溶性，酶敏感性，腫瘤靶向性的智慧型抗乳腺癌藥物—適配子—紫杉醇偶合物」的研究論文，榮獲創新項目的生命科學作品二等獎。黨蕾同學和王迪凱同學題為「成骨細胞內 PLEKHO1 參與類風濕性關節炎炎症和骨修復失敗」的論文，則獲得創新項目的生命科學作品三等獎。Three teams made up of five postgraduate students won two second prizes and one third prize at the “Challenge Cup” National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competition held at the Hong Kong Science Park on 22 and 23 May. While Pan Wenhui and Xia Yixuan won second prize for start-up projects for their project entitled “Avantgarde Formulation of Skin-lightening and Skin-protecting Products with Natural Ingredients”, Lu Jun also won a second prize in the innovation in life sciences category for his research thesis entitled “Develop a Highly Water Soluble Nucleolin Aptamer Paclitaxel Conjugate with a Cathepsin Labile Linker for Tumor Specific Targeting in Ovarian Cancer”. Dang Lei and Shaikh Atik Badshah won third prize in the innovation in life sciences category for their research paper entitled “Osteoblastic PLEKHO1 contributes to articular inflammation and bone repair failure in rheumatoid arthritis”. /



## 學生設計流動健康系統獲獎

### SCM students gain international prize for design of blockchain-based mobile health care system

碩士研究生 Robert Parcus、中醫課程學生周子賀、王俊添與簡迪麟早前參加 AIA Blockchain Challenge，設計中西健康項目（WE Health），榮獲學生組比賽第二名。他們設計的健康生活方式平台揉合了西醫和中醫觀念，利用流動及穿戴式技術監控使用者的健康情況和為他們提供健康資訊建議。MPhil student Robert Parcus teamed up with BCM students George Chow, Tim Wong and Declan Kan won second prize in the student category of the AIA Blockchain Challenge for their “Western and Eastern Health (WE Health)” project. The team’s design entailed the creation of a platform for achieving a healthy lifestyle by using concepts taken from Western and traditional Chinese medicine. Making use of mobile and wearable technologies, the system has features to monitor the health conditions of the users and provide them with health advice. /

## 碩士研究生於國際研討會獲傑出口述報告獎

### MPhil student wins outstanding oral presentation award at international symposium

碩士研究生 Robert Parcus 於 8 月 17 日在香港舉行的國際研究生中醫藥研討會上，發表題為「採集、分析與應用舌圖像的新方法」的報告，榮獲傑出口述報告獎。他的得獎報告介紹研發可用於快速及可靠地收集中醫舌圖像的流動應用程式。MPhil student Robert Parcus won the “Outstanding Oral Presentation” award for his presentation entitled “New Approaches for Tongue Image Collection, Analysis and Applications” at the International Postgraduate Symposium on Chinese Medicine held on 17 August in Hong Kong. His winning presentation described the development of a mobile application for fast and reliable collection of tongue images for traditional Chinese medicine diagnosis. /



## 學院青海服務學習團

### SCM Qinghai service learning tour

學院老師及中醫本科生共 24 人於 6 月 18 至 27 日到青海服務，學生在老師指導下為當地的老弱病人進行針灸及推拿，也向他們講解骨關節健康。這是學院連續第三年舉辦青海服務學習團，讓學生學以致用，服務社會，同時體會除了治療病人的身體，關懷病人也十分重要。學生覺得這項活動十分有意義，希望以後能夠續辦。A group of 24 teachers and BCM students from SCM went on a service learning tour to Qinghai from 18 to 27 June. Under the guidance of teachers, students carried out acupuncture and tui na therapy on some underprivileged elderly patients, and gave them advice on bone and joint health. The third Qinghai tour since its launch in 2015, this activity has enabled the students to serve the community with what they have learned and to appreciate the importance of a caring spirit in addition to treating the physical discomfort of patients. Students hope that this meaningful activity will continue. /





## 學生參與社區健康講座

### SCM students take part in community health talk

為增加中醫本科生臨床實習的經驗及鼓勵他們回饋社會，教學科研部於 8 月 17、18 日在校園舉辦中醫健康資訊公眾講座，由學院老師向參加的市民介紹中醫骨關節病及痛症的預防和治療方法，學生協助進行健康普查，也帶領參加者參觀設於學院大樓的中醫藥博物館及中藥標本中心，增加他們對中醫藥的知識。To provide BCM students with more opportunities for clinical practice and encourage them to contribute to society, SCM organised Chinese medicine health talks for the public on campus on 17 and 18 August. While SCM teachers delivered talks on the prevention and treatment of osteoarthritis and pains, the students carried out a health survey and conducted a tour of the Chinese medicine museum and Chinese medicines centre housed in SCM to enhance the participants' knowledge of Chinese medicine. /



## 本科生暑期外訪交流深化學習

### Undergraduates take part in summer exchange activities

學院一向致力推行全人教育，鼓勵學生走出課堂，擴闊視野。今年暑假，中醫和中藥本科生在老師的帶領下，分別到北京中醫藥大學、湖南中醫藥大學、中山大學中山醫學院、台灣中國醫藥大學中醫學院、上海曙光醫院作學術及文化交流，通過參加專家講座，以及參觀教研設施、附屬醫院、植物園和藥園等，既深化學習又體驗不同文化。Committed to the ethos of whole-person education, SCM has spared no efforts to encourage students to go explore the world to broaden their horizons. This past summer, teacher-led tours to Beijing University of Chinese Medicine, Hunan University of Chinese Medicine, Zhongshan School of Medicine of Sun Yat-sen University, Shanghai Shuguang Hospital and College of Chinese Medicine of China Medical University were organised for students of the BCM and BPharm programmes for academic and cultural exchange. Through talks by experts and tours of learning and research facilities, affiliated hospitals, botanical gardens and herb gardens, the students not only delved deep into their disciplines but gained a better understanding of different cultures. /



## 內地中醫藥大學及澳門中學師生到訪

### Visits by teachers and students of mainland universities and Macao school to SCM

教學科研部於 7 月至 9 月期間接待了逾 100 名分別來自中山大學醫學院及藥學院、澳門聖公會澳門蔡高中學、成都中醫藥大學及湖南中醫藥大學的師生訪問團。除了為到訪師生舉辦中醫骨傷推拿及中藥學等講座，

也安排他們參觀浸大校園及學院設施，促進了三地的學術及文化交流。From July through September, CMTR received over 100 staff and students from the Zhongshan School of Medicine and School of Pharmaceutical Sciences of Sun Yat-Sen University, Sheng Kung Hui Choi Kou School (Macao), Chengdu University of Traditional Chinese Medicine and Hunan University of Chinese Medicine. In addition to organising seminars on *tui na*, orthopaedics and traumatology as well as medicinal botany for the visitors, CMTR conducted tours of the SCM Building as well as the HKBU campus. The visits have fostered academic and cultural exchange between Hong Kong, the mainland and Macao. /

## 新書介紹中醫校友善舉

### Benevolence of SCM alumni introduced in new book

由中醫校友歐卓榮博士、曾穎怡博士、李宇銘博士創辦的非牟利團體「全仁中醫」的宗旨是利用中醫藥幫助貧困地區的人防治疾病，並教導他們中醫藥知識。該書的其中一章介紹三位校友在菲律賓小鎮、泰緬邊境、柬埔寨及青海西寧等偏遠地區義診，體現濟世為懷的醫者之心。該書由國際中醫藥文化節出版，為書寫序言的包括教學科研部主任李敏教授及上述三位校友。The good deeds of BCM alumni Dr. Dennis Au, Dr. Charmaine Tsang and Dr. Vincent Lee, founders of the non-profit-making organisation "Chinese Medicine for All", were reported in a chapter of a new book 《中醫無國界》 (*Chinese Medicine Doctors Without Borders*). The mission of "Chinese Medicine for All" is to help underprivileged in remote places with Chinese medicine and also teach them knowledge of Chinese medicine. A chapter of the book is devoted to how the three young Chinese medicine doctors provided free medical consultation for the sick and underprivileged in a small town in the Philippines, the Thai-Myanmar border and remote places in Cambodia and Xining in Qinghai province. Professor Li Min, Director of Teaching and Research Division, and the three alumni wrote prefaces for the book, which was published by the International Chinese Medicine Cultural Festival. /



仁中醫」獲新書《中醫無國界》推他們中醫藥知識。該書的其中一章介紹三位





顧智湛博士

Dr. Gu Zhizhan

教學科研部助理教授

Assistant Professor,  
Teaching and Research Division

顧博士取得復旦大學醫學博士學位、美國布朗大學生理及生物技術學博士學位後，在美國哈佛大學醫學院從事博士後研究，專攻免疫學。加入浸大前，他於哈佛大學醫學院及附屬布列根和婦女醫院、MD 安德森癌症中心、約翰霍普金斯大學，以及愛因斯坦醫學院擔任研究工作，並擔任美國輝瑞藥業研究院和哈佛大學醫學院及附屬丹娜法伯癌症研究院資深研究員。

顧博士對免疫學、實體瘤微環境和免疫治療有廣泛的研究興趣，專注研究有關癌症、類風濕自體免疫病和神經退行性疾病等醫學領域的細胞黏附、細胞信號轉導、蛋白質運輸、蛋白質組學、免疫治療、以及大分子和小分子的藥物研發等科學研究，同時擅長分子影像學的科技研發。

After receiving his M.D. degree at Fudan University and his Ph.D. degree in molecular pharmacology, physiology and biotechnology at Brown University, USA, Dr. Gu pursued postdoctoral fellow training in immunology at Harvard Medical School (HMS). Prior to joining HKBU, Dr. Gu was on the research faculty of HMS – Brigham & Women's Hospital, MD Anderson Cancer Center, Johns Hopkins University and Albert Einstein College of Medicine, and then a senior staff scientist at Pfizer Inc. and HMS – Dana-Farber Cancer Institute. His work has been published in *Nature Genetics*, *Cell Reports*, *Journal of Cell Biology*, *Proceedings of the National Academy of Sciences of the United States*, *Immunological Reviews*, etc.

With keen interest in immunology, solid tumor microenvironment and immunotherapy, Dr. Gu focuses his research on cell adhesion, cell signaling, protein trafficking, proteomics, immunotherapy and drug discovery (both large and small molecules) in cancer, rheumatoid arthritis, neurodegenerative diseases, etc. He is also specialised in developing molecular imaging techniques.



鄭健剛博士

Dr. Zheng Jiangang

臨床部高級講師

Senior Lecturer,  
Clinical Division

鄭博士畢業於天津中醫學院，先後取得學士學位、針灸碩士學位及針灸博士學位，師從中國工程院院士、國醫大師石學敏教授。曾任天津中醫學院第一附屬醫院主任醫師、教授及碩士研究生導師。鄭博士從事中醫臨床、教學、科研工作 20 餘年，專業研究範圍為以針灸應用於各種痛症、中風偏癱、神經肌肉病變等，並擔任多個專業委員會的委員及學術雜誌的編委。

Dr. Zheng obtained from the Tianjin University of Traditional Chinese Medicine (TJUTCM) his bachelor's degree, master's degree and Ph.D. degree, both in acupuncture and moxibustion. He studied under Professor Shi Xuemin, Academician, Chinese Academy of Engineering and National TCM Master. Dr. Zheng was a chief practitioner, professor and supervisor of postgraduate students at the Department of Acupuncture of the First Teaching Hospital of TJUTCM. Dr. Zheng has been engaging in Chinese medicine clinical practice, teaching and research for over 20 years; his research focuses on the use of acupuncture to treat various pains, stroke hemiplegia, neuromuscular disorders, etc. His professional activities include service on a number of professional committees and editorial boards of academic journals.



孟慶年

Mr. Meng Qingnian

臨床部一級講師

Lecturer I,  
Clinical Division

孟醫師畢業於黑龍江中醫藥大學，曾就職於黑龍江省中醫藥科技成果門診部晉升至中醫主任醫師。加入香港浸會大學中醫藥學院前，曾於香港大學專業進修學院從事臨床及教學工作。孟醫師的專業研究範圍包括以中藥治療內分泌代謝及內科疑難雜病，如糖尿病併發症、橋本氏甲狀腺炎、痛風性腎病症等疾病。他曾參與主持科研工作，發表論文多篇，並擔任多部著作的主編及參編。

Mr. Meng graduated from the Heilongjiang University of Chinese Medicine. He worked at the Harbin Jiren Traditional Chinese Medicine Hospital and was promoted to Chief Practitioner. Prior to joining HKBU, he practised Chinese medicine and taught at HKU School of Professional and Continuing Education. Mr. Meng's research focuses on using Chinese medicine to treat endocrine and metabolic diseases, such as diabetes complications, Hashimoto's thyroiditis and gouty kidney, etc. He has led and participated in various research projects, and served as the editor-in-chief and editor of a number of publications.



## 香港浸會大學中醫藥學院

九龍塘浸會大學道七號賽馬會中醫藥學院大樓

### School of Chinese Medicine, Hong Kong Baptist University

Jockey Club School of Chinese Medicine Building,  
7 Baptist University Road, Kowloon Tong, Kowloon.

#### 院長辦公室

Dean's Office

##### 四樓 4/F

電話 Tel (852) 3411 2457  
傳真 Fax (852) 3411 2917  
電郵 Email [scmd@hkbu.edu.hk](mailto:scmd@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk>

#### 教學科研部

Teaching and Research Division

##### 四樓 4/F

電話 Tel (852) 3411 2481  
傳真 Fax (852) 3411 2461  
電郵 Email [cmtr@hkbu.edu.hk](mailto:cmtr@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/academicprogrammes>

#### 技術開發部

Technology Development Division

##### 四樓 4/F

電話 Tel (852) 3411 2945  
傳真 Fax (852) 3411 2902  
電郵 Email [scmtdd@hkbu.edu.hk](mailto:scmtdd@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/tdd>

#### 臨床部

Clinical Division

##### 三樓 3/F

電話 Tel (852) 3411 2968 / (852) 3411 2988  
傳真 Fax (852) 3411 2929  
電郵 Email [scmcld@hkbu.edu.hk](mailto:scmcld@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/cmclinic>

#### 持續及專業教育部

Division of Continuing & Professional Education

##### 四樓417室 Rm417, 4/F

電話 Tel (852) 3411 2912 / (852) 3411 5748  
傳真 Fax (852) 3411 2918  
電郵 Email [dcpe@hkbu.edu.hk](mailto:dcpe@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/dcpe>

#### 秘書處

Secretariat

##### 四樓 4/F

電話 Tel (852) 3411 5387  
傳真 Fax (852) 3411 2902  
電郵 Email [scm@hkbu.edu.hk](mailto:scm@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk>